Tilray Brands, Inc. — Annual Report 2020

Feb 19, 2021

Item 8. Financial Statements and Supplementary Data.

INDEX TO CONSOLIDATED FINANCIAL STATEMENTS

Consolidated Balance Sheets as of December 31, 2020 and 2019	81
Consolidated Statements of Net Loss and Comprehensive Loss for the Years ended December 31, 2020,
2019, and 2018	82
Consolidated Statements of Stockholders’Equity (Deficit) for the Years ended December 31, 2020, 2019
and 2018	83
Consolidated Statements of Cash Flows for the Years ended December 31, 2020, 2019 and 2018	84
Notes to Consolidated Financial Statements	85
Report of Independent Registered Public Accounting Firm	126

All financial statement schedules have been omitted, since the required information is not applicable or is not present in amounts sufficient to require submission of the schedule, or because the information required is included in the consolidated financial statements and accompanying notes.

80

TILRAY, INC. Consolidated Balance Sheets

(in thousands of United States dollars, except for share and per share data)

	December 31, 2020	December 31, 2019
Assets
Current assets:
Cash and cash equivalents	$ 189,702	$ 96,791
Accounts receivable, net of allowance for credit losses of $887 and provision for sales returns of $1,651 (December 31, 2019 - $615 and $1,400,respectively)	29,033	36,202
Inventory	93,645	87,861
Prepayments and other current assets	34,640	38,173
Total current assets	347,020	259,027
Propertyand equipment,net	199,559	184,217
Operatinglease,right-of-use assets	17,985	17,514
Intangible assets,net	186,445	228,828
Goodwill	166,915	163,251
Equitymethod investments	9,300	11,448
Other investments	14,369	24,184
Other assets	4,356	7,861
Total assets	$ 945,949	$ 896,330
Liabilities
Current liabilities
Accountspayable	17,776	39,125
Accrued expenses and other current liabilities	39,946	50,829
Accrued lease obligations	2,913	2,473
Warrant liability	120,647	—
Total current liabilities	181,282	92,427
Accrued lease obligations	30,623	29,407
Deferred tax liability	49,274	53,363
Convertible notes,net of issuance costs	257,789	430,210
Senior Facility,net of transaction costs	48,470	—
Other liabilities	4,612	5,652
Total liabilities	$ 572,050	$ 611,059
Commitments and contingencies(refer to Note 20)
Stockholders’ equity
Class 1 common stock ($0.0001 par value, 233,333,333 and 250,000,000 shares authorized; 0 and 16,666,667 shares issued and outstanding)	—	2
Class 2 common stock ($0.0001 par value; 500,000,000 shares authorized; 158,456,087 and 86,114,558 shares issued and outstanding, respectively)	16	9
Additionalpaid-in capital	1,095,781	705,671
Accumulated other comprehensive income	8,205	9,719
Accumulated deficit	(730,103 )	(430,130 )
Total stockholders' equity	$ 373,899	$ 285,271
Total liabilities and stockholders' equity	$ 945,949	$ 896,330

The accompanying notes are an integral part of these consolidated financial statements.

81

TILRAY, INC.

Consolidated Statements of Net Loss and Comprehensive Loss

(in thousands of United States dollars, except for share and per share data)

	Years ended December 31,	Years ended December 31,	Years ended December 31,
	2020	2019	2018
Revenue	$ 210,482	$ 166,979	$ 43,130
Cost of sales	185,827	190,475	28,855
Grossprofit(loss)	24,655	(23,496 )	14,275
General and administrative expenses	85,883	110,903	48,577
Sales and marketingexpenses	54,666	63,813	15,828
Research and development expenses	4,411	9,172	5,864
Depreciation and amortization expenses	13,722	11,607	1,598
Impairment of assets	61,114	112,070	—
Acquisition-related(income)expenses,net	—	(31,427 )	248
Loss from equitymethod investments	5,983	4,504	—
Operatingloss	(201,124 )	(304,138 )	(57,840 )
Foreign exchange(gain)loss,net	(13,169 )	(5,944 )	7,234
Change in fair value of warrant liability	100,286	—	—
Gain on debt conversion	(61,118 )	—	—
Interest expenses,net	39,219	34,690	9,110
Finance income from ABG	—	(764 )	—
Other expenses(income),net	10,333	(2,501 )	(2,010 )
Loss before income taxes	(276,675 )	(329,619 )	(72,174 )
Deferred income tax recoveries	(5,376 )	(8,847 )	(4,485 )
Current income tax(recoveries)expenses	(226 )	397	34
Net loss	$ (271,073 )	$ (321,169 )	$ (67,723 )
Net lossper share - basic and diluted	$ (2.15 )	$ (3.20 )	$ (0.82 )
Weighted average shares used in computation of net loss per share - basic and diluted	126,041,710	100,455,677	83,009,656
Net loss	(271,073 )	(321,169 )	(67,723 )
Foreign currencytranslation(loss) gain,net	(1,497 )	5,174	662
Unrealized loss on investments	(17 )	(21 )	(765 )
Other comprehensive income(loss)	(1,514 )	5,153	(103 )
Comprehensive loss	$ (272,587 )	$ (316,016 )	$ (67,826 )

The accompanying notes are an integral part of these consolidated financial statements.

82

TILRAY, INC.

Consolidated Statements of Stockholders’ Equity (Deficit)

(in thousands of United States dollars, except for share and per share data)

	Prefer	red es		stock	Additional	Accumulated other		Total stockholders'
	shar		Common
	Number of shares	Amount	Number of shares	Amount	paid-in capital	comprehensive income	Accumulated deficit	equity (deficit)
Balance at December 31,2017	—	—	—	—	31,736	3,866	(40,454 )	(4,852 )
Shares issued forpreferred shares,net of issuance costs	7,794,042	2	—	—	52,558	—	—	52,560
Conversion ofpreferred shares	(7,794,042 )	(2 )	7,794,042	2	—	—	—	—
Common stock issuance,net of issuance costs	—	—	85,350,000	8	160,784	—	—	160,792
Stock-based compensation expenses	—	—	—	—	20,988	—	—	20,988
Other comprehensive loss	—	—	—	—	—	(103 )	—	(103 )
Deferred tax liabilityrelated to convertible notes,net of issuance costs	—	—	—	—	(8,809 )	—	—	(8,809 )
Issuance of shares for Alef acquisition	—	—	26,825	—	2,855	—	—	2,855
Equity component related to issuance of convertible notes, net of issuance costs	—	—	—	—	41,945	—	—	41,945
Net loss	—	—	—	—	—	—	(67,723 )	(67,723 )
Balance at December 31,2018	—	—	93,170,867	10	302,057	3,763	(108,177 )	197,653
Cumulative effect adjustment from transition to ASU 2016-01	—	—	—	—	—	803	(803 )	—
Cumulative effect adjustment from transition to ASC 842	—	—	—	—	—	—	19	19
Shares issued for Natura acquisition	—	—	180,332	—	15,099	—	—	15,099
Shares issued for Natura contingent consideration	—	—	238,826	—	4,450	—	—	4,450
Shares issued for Manitoba Harvest acquisition	—	—	2,109,252	—	128,710	—	—	128,710
Shares issued for ABG Profit Participation Arrangement	—	—	1,680,214	—	125,097	—	—	125,097
ABG finance receivable,net of finance income of$2,700	—	—	—	—	(27,553 )	—	—	(27,553 )
Shares issued for common stock at-the-market,net of issuance costs	—	—	5,396,501	1	111,072	—	—	111,073
Shares issued for investments	—	—	550,646	—	10,551	—	—	10,551
Shares issued for S & S acquisition	—	—	79,289	—	3,189	—	—	3,189
Shares issued under stock-based compensationplans	—	—	1,575,455	—	506	—	—	506
Shares issued for employee compensation	—	—	11,868	—	651	—	—	651
Stock-based compensation expenses	—	—	—	—	31,842	—	—	31,842
Downstream merger	—	—	(2,212,025 )	—	—	—	—	—
Other comprehensive income	—	—	—	—	—	5,153	—	5,153
Net loss	—	—	—	—	—	—	(321,169 )	(321,169 )
Balance at December 31, 2019	—	—	102,781,225	$ 11	$ 705,671	$ 9,719	$ (430,130 )	$ 285,271
Proceeds from ABG Profit Participation Agreement	—	—	—	—	1,353	—	—	1,353
Write-off of ABG finance receivable	—	—	—	—	28,900	—	(28,900 )	—
Escrow shares released from downstream merger	—	—	(61,776 )	—	(644 )	—	—	(644 )
Shares issued under registered offering,net of issuance costs	—	—	7,250,000	1	19,828	—	—	19,829
Shares issued for exercise ofpre-funded warrants	—	—	11,750,000	1	49,054	—	—	49,055
Shares issued for investments	—	—	6,934	—	—	—	—	—
Shares issued under stock-based compensationplans	—	—	2,972,022	—	11,284	—	—	11,284
Shares issued for common stock at-the-market,net of issuance costs	—	—	16,131,487	1	125,142	—	—	125,143
Shares issued for contract settlements	—	—	286,618	—	2,215	—	—	2,215
Shares issued for convertible debt settlement	—	—	17,339,577	2	123,262	—	—	123,264
Stock-based compensation expenses	—	—	—	—	29,716	—	—	29,716
Other comprehensive income	—	—	—	—	—	(1,514 )	—	(1,514 )
Net loss	—	—	—	—	—	—	(271,073 )	(271,073 )
Balance at December 31, 2020	—	$ —	$ 158,456,087	$ 16	$ 1,095,781	$ 8,205	$ (730,103 )	$ 373,899

The accompanying notes are an integral part of these consolidated financial statements.

83

TILRAY, INC.

Consolidated Statements of Cash Flows

(in thousands of United States dollars, except for per share data)

	Y	ear ended December 31,
	2020	2019	2018
Operating activities
Net loss	$ (271,073 )	$ (321,169 )	$ (67,723 )
Adjusted for the followingitems:
Inventoryvaluation adjustments	38,419	68,583	384
Depreciation and amortization expenses	18,654	15,849	3,562
Impairment of assets	61,114	112,070	—
Stock-based compensation expenses	29,716	31,842	20,988
Change in fair value of warrant liability	100,286	—	—
Gain on sale of short-term investment	—	(2,631 )	—
Change in fair value of contingent consideration	—	(46,914 )	—
Loss from equitymethod investments	5,983	4,504	—
Loss from equityinvestments measured at fair value	4,283	939	6
Loss from sale of investment	2,440	—	—
Interest on debt securities	(798 )	(149 )	—
Deferred taxes	(5,376 )	(8,847 )	(4,485 )
Amortization of discount on convertible notes	10,317	9,843	2,180
Amortization of transaction costs on Senior Facility	1,372	—	—
Foreign currency (gain)loss	(13,169 )	(5,944 )	6,477
Accretion related to obligations under finance leases	1,435	367	—
Issuance costs on registered offeringrecorded to net loss	3,953	—	—
Non-cash interest expenses	1,643	—	5,669
Credit loss expenses	401	—	—
Provision for doubtful accounts	251	1,723	285
Loss(gain)on disposal ofpropertyand equipment	1,851	2,436	(2 )
Gain on Convertible Debt,Net	(61,118 )	—	—
Changes in non-cash workingcapital:
Accounts receivable	6,291	(14,820 )	(16,512 )
Inventory	(30,065 )	(102,643 )	(9,226 )
Prepayments and other current assets	(5,404 )	(51,408 )	(2,487 )
Accountspayable	(20,485 )	20,003	5,218
Accrued expenses and other liabilities	(10,272 )	28,301	9,418
Net cash used in operatingactivities	(129,351 )	(258,065 )	(46,248 )
Investing activities
Business combinations,net of cash acquired	—	(163,889 )	—
Investment in ABG Profit Participation Arrangement	—	(33,333 )	—
Investment in equitymethod investees	(3,764 )	(14,201 )	—
Change in deposits and other assets	—	(2,689 )	—
Purchases of short-term and other investments	—	(1,350,666 )	(319,373 )
Proceeds from sales and maturities of short-term investments	4,067	1,383,632	274,497
Purchases ofpropertyand equipment	(44,644 )	(73,741 )	(50,198 )
Proceeds from disposal ofpropertyand equipment	2,661	6,581	713
Purchases of intangible assets	—	(4,875 )	(4,259 )
Net cash used in investingactivities	(41,680 )	(253,181 )	(98,620 )
Financing activities
Proceeds from at-the market equityoffering,net of costs	124,500	111,073	—
Proceeds from issuance of registered offering,net of issuance costs	85,465		—
Proceeds from ABG Profit Participation Arrangement	1,353	4,187	—
Payment of ABG finance liability	(1,500 )	(500 )	—
Payment under Privateer Holdings debt facilities	— `	—	(36,940 )
Advances under Privateer Holdings debt and construction facilities	—	—	3,453
Proceeds from Preferred Shares - Series A,net of transaction costs	—	—	52,560
Proceeds from exercise of stock options	11,502	5,458	—
Payment on the settlement of stock options	(1,263 )	(5,014 )	—
Payment of mortgage debt	—	—	(9,136 )
Payment of obligations under finance lease	—	(504 )	—
Proceeds from issuance of Senior Facility,net of transaction costs	46,395	—	—
Repayment of Senior Facility	(1,605 )	—	—
Proceeds from issuance of convertible notes,net of issuance costs	—	—	460,269
Proceeds from issuance of common stockpursuant to IPO,net	—	—	160,792
Net cashprovided byfinancingactivities	264,847	114,700	630,998
Effect of foreign currencytranslation on cash and cash equivalents	(905 )	6,082	(1,198 )
Cash and cash equivalents
Increase(decrease)in cash and cash equivalents	92,911	(390,464 )	484,932
Cash and cash equivalents,beginningofperiod	96,791	487,255	2,323
Cash and cash equivalents, end of period	$ 189,702	$ 96,791	$ 487,255

The accompanying notes are an integral part of these consolidated financial statements.

84

TILRAY, INC. Notes to Consolidated Financial Statements

(in thousands of United States dollars, except for per share data)

1. Description of Business and Summary

Tilray, Inc., a Delaware corporation, and its wholly owned subsidiaries (collectively “Tilray”, the “Company”, “we”, “our”, or “us”), is a global medical cannabis research, cultivation, processing and distribution organization, and is one of the leading suppliers of adult-use cannabis in Canada. The Company also markets and distributes food products from hemp seed and offers a broad range of natural and organic hemp based food products and ingredients that are sold through retailers and websites globally.

Prior to January 2018, the Company operated its business under Decatur Holdings, B.V. (“Decatur”), which was formed in March 2016. Decatur was incorporated under the laws of the Netherlands on March 8, 2016 as a wholly owned subsidiary of Privateer Holdings, Inc. (“Privateer Holdings”). On January 25, 2018, Privateer Holdings transferred the equity interest in Decatur to Tilray. Decatur was subsequently dissolved on December 27, 2018. The transfers of the equity interests were between entities under common control and were recorded at their carrying amounts. The consolidated financial statements of the Company (“the financial statements”) are prepared, on a continuity of interest basis, reflecting the historical financial information of Decatur prior to January 25, 2018.

On December 15, 2020, we entered into an Arrangement Agreement (the “Arrangement Agreement” with Aphria Inc. (“Aphria”), pursuant to which Tilray will acquire all of the issued and outstanding common shares of Aphria pursuant to a plan of arrangement (the “Plan of Arrangement”) under the Business Corporations Act (the “Arrangement”). Subject to the terms and conditions set forth in the Arrangement Agreement and the Plan of Arrangement, each outstanding common share of Aphria outstanding immediately prior to the effective time of the Arrangement will be transferred to Tilray in exchange for 0.8381 of a share (of Tilray Class 2 common stock). The Agreements have not been finalized and as such, the financial statements do not reflect the effect of the transaction.

2. Summary of Significant Accounting Policies

Basis of presentation

The accompanying consolidated financial statements reflect the accounts of the Company. The financial statements were prepared in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”) and pursuant to the rules and regulations of the United States Securities and Exchange Commission (“SEC”).

These financial statements have been prepared on a going concern basis, which assumes that the Company will continue in operation for the foreseeable future and, accordingly, will be able to realize its assets and discharge its liabilities in the normal course of operations as they come due.

For the fiscal year ended December 31, 2020 the Company reported a consolidated net loss of $271,073 and a consolidated net loss of $321,169 and $67,723 for the years ending December 31, 2019 and December 31, 2018, respectively.

For the years ended December 31, 2020, 2019 and 2018, the Company had cash flows used in operating activities of $129,351, $258,065 and $46,248, respectively. The Company had net cash inflows for the year ended December 31, 2020 of $92,911.

As at December 31, 2020 and 2019, the Company had working capital of $165,738 and $166,600 respectively, reflecting an increase in cash of $92,911, a reduction in payables of $32,232, and the addition of $120,647 in warrant liability for the year ending December 31, 2020.

Current management forecasts and related assumptions support the view that the Company can adequately manage the operational needs of the business with the current cash on hand for the next twelve months from the date of issuance of these financial statements.

These financial statements reflect all adjustments, which, in the opinion of management, are necessary for a fair presentation of the Company’s financial position and results of operations.

85

Basis of consolidation

These financial statements include the accounts of the following entities wholly owned by the Company as of December 31, 2020:

of December 31, 2020:
Name of entity	Date of formation	Place of incorporation
Natura Naturals Inc.	May 31, 1985	Canada
Tilray, Inc.	July 8, 2005	United States
Manitoba Harvest USA LLC	February 8, 2010	United States
Tilray Canada, Ltd.	September 6, 2013	Canada
Dorada Ventures, Ltd.	October 18, 2013	Canada
FHF Holdings Ltd.	July 15, 2015	Canada
High Park Farms Ltd.	February 19, 2016	Canada
Tilray Deutschland GmbH	November 3, 2016	Germany
Pardal Holdings, Lda.	April 5, 2017	Portugal
Tilray Portugal Unipessoal, Lda.	April 20, 2017	Portugal
Tilray Australia New Zealand Pty. Ltd.	May 9, 2017	Australia
Tilray Ventures Ltd.	June 6, 2017	Ireland
Manitoba Harvest Japan K.K.	August 29, 2017	Japan
High Park Holdings, Ltd.	February 8, 2018	Canada
Fresh Hemp Foods Ltd.	May 7, 2018	Canada
Natura Naturals Holdings Inc.	May 17, 2018	Canada
National Cannabinoid Clinics Pty Ltd.	September 19, 2018	Australia
Tilray Latin America SpA	November 19, 2018	Chile
Tilray Portugal II, Lda.	December 11, 2018	Portugal
High Park Gardens Inc.	February 7, 2019	Canada
1197879 B.C. Ltd	February 15, 2019	Canada
High Park Shops Inc.	August 15, 2019	Canada
Privateer Evolution, LLC	December 12, 2019	United States
Tilray France SAS	July 2, 2020	France
High Park Holdings B.V.	July 15, 2020	Netherlands
High Park Botanicals B.V.	July 17, 2020	Netherlands

The entities listed above are wholly owned by the Company and have been formed or acquired to support the intended operations of the Company and all intercompany transactions and balances have been eliminated in the financial statements of the Company.

The financial statements also include variable interest entities (“VIE”). A VIE is a legal entity that does not have sufficient equity at risk to finance its activities without additional subordinated financial support, is structured such that equity investors lack the ability to make significant decisions relating to the entity’s operations through voting rights, or do not substantively participate in the gains and losses of the entity. Upon inception of a contractual agreement, the Company performs an assessment to determine whether the arrangement contains a variable interest in a legal entity and whether that legal entity is a VIE. The primary beneficiary has both the power to direct the activities of the VIE that most significantly impact the entity’s economic performance and the obligation to absorb losses or the right to receive benefits from the VIE entity that could potentially be significant to the VIE. Where the Company concludes it is the primary beneficiary of a VIE, the Company consolidates the accounts of that VIE. When the Company is not the primary beneficiary, the VIE is accounted for using the equity method and is included in equity method investments on the balance sheets. At December 31, 2020, 2019 and 2018, the Company had no consolidated VIEs. Refer to Note 7 for the Company’s VIEs accounted for using the equity method.

The Company regularly reviews and reconsiders previous conclusions regarding whether it is the primary beneficiary of a VIE. The Company also reviews and reconsiders previous conclusions regarding whether the Company holds a variable interest in a potential VIE, the status of an entity as a VIE, and whether the Company is required to consolidate such a VIE in the financial statements when a change occurs.

86

New accounting pronouncements recently adopted

Allowance for credit losses

In June 2016, the Financial Accounting Standard Board, (“FASB”) issued Accounting Standard Update (“ASU”) 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. This guidance was subsequently amended by ASU 2018-19, Codification Improvements, ASU 201904, Codification Improvements, ASU 2019-05, Targeted Transition Relief, ASU 2019-10, Effective Dates, and ASU 2019-11, Codification Improvements. These ASUs are referred to collectively as the new guidance on current expected credit loss (“CECL”). As a result of the adoption of the new CECL guidance on January 1, 2020, the Company has changed its accounting policy for the allowance for credit losses, as it relates to accounts receivable and available-for-sale debt securities. The adoption of the CECL guidance did not have a material impact on the financial statements at January 1, 2020.

Disclosure framework – fair value measurement

In August 2018, the FASB issued ASU 2018-13, Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement (Topic 820) (“ASU 2018-13”). ASU 2018-13 removes (a) the prior requirement to disclose the amount and reason for transfers between Level 1 and Level 2 of the fair value hierarchy contained in ASC Topic 820, (b) the policy for timing of transfers between levels, and (c) the valuation process used for Level 3 fair value measurements. ASU 2018-13 also adds, among other items, a requirement to disclose the range and weighted average of significant unobservable inputs used in Level 3 fair value measurements. The Company adopted ASU 2018-13 effective January 1, 2020 and such adoption did not have a material effect on its financial statements.

Use of estimates and significant judgments

The preparation of the Company’s financial statements requires management to make estimates, assumptions and judgments that affect the reported amounts of revenue, expenses, assets, liabilities, accompanying disclosures and the disclosure of contingent liabilities. These estimates and judgments are subject to change based on experience and new information which could result in outcomes that require a material adjustment to the carrying amounts of assets or liabilities affecting future periods. Estimates and judgments are assessed on an ongoing basis. Revisions to estimates are recognized prospectively.

Examples of key estimates in these financial statements include the value of Class 2 common shares with transfer restrictions, asset impairment including the impact of COVID-19 on estimated future cash flows and fair values, imputed interest for loans receivable, the allowance for credit losses, provisions for prepayments and other current assets, inventory valuation adjustments that contemplate the market value of, and demand for inventory, estimated useful lives of property and equipment and intangible assets, valuation allowance on deferred income tax assets, determining the fair value of financial instruments, fair value of stock-based compensation, estimated variable consideration on contracts with customers, sales return estimates, the fair value of the convertible notes and equity component and the classification, the fair value of the warrant liability using a Monte Carlo pricing model, incremental borrowing rates and lease terms applicable to lease contracts.

Financial statement areas that require significant judgments are as follows:

Variable interest entities - The Company assesses all variable interests in entities and uses judgment when determining if the Company is the primary beneficiary. Other qualitative factors that are considered include decision-making responsibilities, the VIE capital structure, risk and rewards sharing, contractual agreements with the VIE, voting rights and the level of involvement of other parties.

Asset impairment – Asset impairment tests require the allocation of assets to asset groups, where appropriate, which requires significant judgment and interpretation with respect to the integration between the assets and shared resources. Asset impairment tests require the determination of whether there is an indication of impairment. The assessment of whether an indication of impairment exists is performed at the end of each reporting period and requires the application of judgment, historical experience, and external and internal sources of information.

Leases – The Company applies judgment in determining whether a contract contains a lease and if a lease is classified as an operating lease or a finance lease. The Company determines the lease term as the non-cancellable

87

term of the lease, which may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option.

The Company has several lease contracts that include extension and termination options. The Company applies judgment in evaluating whether it is reasonably certain whether or not to exercise the option to renew or terminate the lease. That is, it considers all relevant factors that create an economic incentive for it to exercise either the renewal or termination. After the commencement date, the Company reassesses the lease term if there is a significant event or change in circumstances that is within its control and affects its ability to exercise or not to exercise the option to renew or to terminate (e.g., construction of significant leasehold improvements or significant customization to the leased asset).

The Company also applies judgment in allocating the consideration in a contract between lease and nonlease components. It considers whether the Company can benefit from the right-of-use asset either on its own or together with other resources and whether the asset is highly dependent on or highly interrelated with another rightof-use asset.

Reclassifications

The Company reclassified previously disclosed amounts related to inventory valuation adjustments and stock-based compensation expenses to conform with the disclosures as of December 31, 2020.

Inventory valuation adjustments were previously disclosed as a separate component of cost of sales on the Company’s Consolidated Statements of Net Loss and Comprehensive Loss. As of December 31, 2020, these amounts are included under the caption of cost of sales.

amounts are included under the caption of cost of sales.
	Year Ended December 31,
	2019 2018
Inventory valuation adjustment no longer disclosed separately
	$ 68,583 $ 4,561
from cost of sales

Stock-based compensation expenses was previously presented as a separate line item in the Company’s Consolidated Statements of Net Loss and Comprehensive Loss. As of December 31, 2020, the Company includes its stock-based compensation expense under the respective caption in financial statements where compensation paid to the same employees is recorded. These reclassifications are summarized as follows:

	Year Ended December 31,
	2019 2018
General and administrative expenses	$ 26,499 $ 18,926
Sales and marketingexpenses	2,729 462
Research and development expenses	2,614 1,600

The Consolidated Statements of Net Loss and Comprehensive Loss for the years ended December 31, 2019 and 2018 were reclassified to conform to the current period’s presentation. Loss on disposal of property and equipment, formerly presented in other expenses (income) is now presented in general and administrative expenses.

Foreign currency

These financial statements are presented in the United States dollar (“USD”), which is the Company’s reporting currency. Functional currencies for the entities in these financial statements are their respective local currencies, including USD, Canadian dollar (“CAD”), Euro, Australian dollar, Chilean Peso, Great Britain Pound and Japanese Yen.

The assets and liabilities of each of the Company’s subsidiaries are translated to USD at the foreign exchange rate in effect at the balance sheet date. Certain transactions affecting the stockholders’ equity (deficit) are translated at historical foreign exchange rates. The consolidated statements of net loss and comprehensive loss and statements of cash flows are translated to USD by applying the average foreign exchange rate in effect during the reporting period. The resulting translation adjustments are included in other comprehensive loss.

The Company’s monetary assets and liabilities denominated in foreign currencies are translated to the functional currency by applying the foreign exchange rate in effect at the balance sheet date. Revenues and expenses are translated using the average foreign exchange rate in effect during the reporting period. Realized and unrealized foreign currency differences are recognized in the statements of net loss and comprehensive loss.

88

Net loss per share

Basic net loss per share is computed by dividing reported net loss by the weighted average number of common shares outstanding for the reported period. Diluted net loss per share reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock of the Company during the reporting period. Diluted net loss per share is computed by dividing net loss by the sum of the weighted average number of common shares and the number of potential dilutive common share equivalents outstanding during the period. Potential dilutive common share equivalents consist of the incremental common shares issuable upon the exercise of vested share options and the incremental shares issuable upon conversion of the convertible notes. Potential dilutive common share equivalents consist of stock options, restricted stock units (“RSUs”) and restricted stock awards.

In computing diluted earnings per share, common share equivalents are not considered in periods in which a net loss is reported, as the inclusion of the common share equivalents would be anti-dilutive. As of December 31, 2020, there were 28,784,308 common share equivalents with potential dilutive impact (2019 – 10,532,988, 2018 – 7,902,263). Since the Company is in a net loss for all periods presented in these financial statements, there is no difference between the Company’s basic and diluted net loss per share for the periods presented.

Business combinations and goodwill

The Company accounts for business combinations using the acquisition method in accordance with ASC 805, Business Combinations, which requires recognition of assets acquired and liabilities assumed, including contingent assets and liabilities, at their respective fair values on the date of acquisition. Any excess of the purchase consideration over the net fair value of tangible and identified intangible assets acquired less liabilities assumed is recorded as goodwill. The costs of business acquisitions, including fees for accounting, legal, professional consulting and valuation specialists, are expensed as incurred within acquisition-related (income) expenses, net. Purchase price allocations may be preliminary and, during the measurement period not to exceed one year from the date of acquisition, changes in assumptions and estimates that result in adjustments to the fair value of assets acquired and liabilities assumed are recorded in the period the adjustments are determined.

For business combinations achieved in stages, the Company’s previously held interest in the acquiree is remeasured at its acquisition date fair value, with the resulting gain or loss recorded in the statements of net loss and comprehensive loss. For a pre-existing relationship between the Company and the acquiree that is not extinguished on the business combination, such a relationship is considered effectively settled as part of the business combination even if it is not legally cancelled. At the acquisition date, it becomes an intercompany relationship and is eliminated upon consolidation.

The estimated fair value of acquired assets and assumed liabilities are determined primarily using a discounted cash flow approach, with estimated cash flows discounted at a rate that the Company believes a market participant would determine to be commensurate with the inherent risks associated with the asset and related estimated cash flow streams. Contingent consideration in a business combination is remeasured at fair value each reporting period until the contingency is resolved and any change in fair value from either the passage of time or events occurring after the acquisition date, is recorded within acquisition-related (income) expenses, net on the statements of net loss and comprehensive loss.

Cash and cash equivalents

Cash and cash equivalents are comprised of cash and highly liquid investments that are readily convertible into known amounts of cash with original maturities of three months or less.

Cash and cash equivalents include amounts held in USD, CAD, Euro, Australian dollar, Chilean Peso, Great Britain Pound, Japanese Yen, corporate bonds, commercial paper, treasury bills and money market funds.

Accounts receivable and allowance for credit losses

Accounts receivable – the Company maintains an allowance for credit losses at an amount sufficient to absorb losses inherent in its accounts receivable portfolio as of the reporting dates based on the projection of expected credit losses.

The Company applies the aging method to estimate the allowance for expected credit losses. The aging method is applied to accounts receivables at the business unit level to reflect shared risk characteristics, such as

89

receivable type, customer type and geographical location. The aging method assigns accounts receivables to a level of delinquency and applies loss rates to each class based on historical loss experience. The Company also considers relevant qualitative and quantitative factors to assess whether historical loss experience should be adjusted to better reflect the risk characteristics of the current classes and the expected future loss. This assessment incorporates all available information relevant to considering the collectability of its current classes, including considering economic and business conditions, default trends, changes in its class composition, among other internal and external factors. The expected credit loss estimates are adjusted for current conditions and reasonable supportable forecasts.

As part of the Company’s analysis of expected credit losses, it may analyze contracts on an individual basis in situations where such accounts receivables exhibit unique risk characteristics and are not expected to experience similar losses to the rest of their class.

Available-for-sale debt securities – The Company assesses its available-for-sale debt securities for impairment at each measurement date. When the fair value is less than the amortized cost, the Company assesses whether it intends to sell the security. When it is assessed that the Company will sell the security or the Company will be required to sell before recovery, the difference between the fair value and amortized cost is recorded as an impairment of assets in the statements of net loss and comprehensive loss. When the Company does not intend to sell and it is not more likely than not that the Company will be required to sell before recovery, the Company assesses whether a portion of the unrealized loss is a result of a credit loss. The Company recognizes the portion related to credit loss as credit loss expenses in general and administrative expenses within the statements of net loss and comprehensive loss and the portion of unrealized loss related to factors other than credit losses in other comprehensive loss. The Company determines the best estimate of the present value of cash flows expected to be collected from the available-for-sale debt securities on an individual basis based on past events, current conditions and forecasts relevant to the individual securities.

Inventory

Inventory is comprised of raw materials, finished goods and work-in-progress. Cost includes expenditures directly related to the manufacturing process as well as suitable portions of related production overheads, based on normal operating capacity.

Cannabis: Inventory costs include pre-harvest, post-harvest, shipment and fulfillment, as well as costs related to accessories. Pre-harvest costs include labor and direct materials to grow cannabis, which includes water, electricity, nutrients, integrated pest management, growing supplies and allocated overhead. Post-harvest costs include costs associated with drying, trimming, blending, extracting, purifying, quality testing and allocated overhead. Shipment and fulfillment costs include the costs of packaging, labelling, courier services, allocated overhead, and excise taxes.

Hemp: Inventory cost includes seeds, packaging and co-packing. Seed costs include commodity cost paid to farmers, genetic seed cost to provide and manage contracted farmers, hulling and processing costs, including labor and overhead. Packaging costs include packaging materials, labor and overhead to run machinery. Co-packing cost are generally for products not manufactured by the Company directly and would include all costs to produce the products.

Inventory is stated at the lower of cost or net realizable value, determined using weighted average cost. Net realizable value is defined as the estimated selling price in the ordinary course of business, less reasonably predictable costs of completion, disposal and transportation. At the end of each reporting period, the Company performs an assessment of inventory and records write-downs for excess and obsolete inventories based on the Company’s estimated forecast of product demand, production requirements, market conditions, regulatory environment, and spoilage. Actual inventory losses may differ from management’s estimates and such differences could be material to the Company’s balance sheets, statements of net loss and comprehensive loss and statements of cash flows.

Property and equipment

Property and equipment are recorded at cost net of accumulated depreciation and impairment, if any. Depreciation is computed using the straight-line method over the estimated useful lives of the assets. The estimated useful life of buildings ranges from twenty to twenty-five years and the estimated useful life of property and

90

equipment, other than buildings, ranges from three to fifteen years. Land is not depreciated. Leasehold improvements are depreciated over the lesser of the asset’s estimated useful life or the remaining lease term.

When assets are retired or disposed of, the cost and accumulated depreciation are removed from the respective accounts and any related gain or loss is recognized. Maintenance and repairs are charged to expenses as incurred. Significant expenditures, which extend the useful lives of assets or increase productivity, are capitalized. When significant parts of an item of property and equipment have different useful lives, they are accounted for as separate items or components of property and equipment.

Construction-in-process includes construction progress payments, deposits, engineering costs, interest expense on long-term construction projects and other costs directly related to the construction of the facilities. Expenditures are capitalized during the construction period and construction in progress is transferred to the relevant class of property and equipment when the assets are available for use, at which point the depreciation of the asset commences.

The estimated useful lives are reviewed at the end of each reporting period, with the effect of any changes in estimate being accounted for on a prospective basis.

Interest incurred relating to the construction or expansion of facilities is capitalized to the construction in progress. The Company ceases the capitalization of interest when construction activities are substantially completed and the facility is available for commercial use.

Intangible assets

Intangible assets include intangible assets acquired as part of business combinations, asset acquisitions and other business transactions. The Company records intangible assets at cost, net of accumulated amortization and accumulated impairment losses, if any. Cost is measured based on the fair values of cash consideration paid and equity interests issued. The cost of an intangible asset acquired is its acquisition date fair value.

The Company capitalizes certain internal-use software development costs, consisting primarily of contractor costs and employee salaries and benefits allocated to the software. Capitalization of costs incurred in connection with internally developed software commences when both the preliminary project stage is completed and management has authorized further funding for the project, based on a determination that it is probable the project will be completed and used to perform the function intended. Capitalization of costs ceases no later than the point at which the project is substantially complete and ready for its intended use. All other costs are expensed as incurred. Amortization is calculated on a straight-line basis over three years. Costs incurred for enhancements that are expected to result in additional functionalities are capitalized.

Amortization of definite life intangible assets is calculated on a straight-line basis over the estimated useful lives of the assets as follows:

as follows:
Patents	4 years
Customer relationships	14 to 16 years
Developed technology	10 years
Websites	3 years
Definite life trademarks and licenses	Term of agreements

When there is no foreseeable limit on the period of time over which an intangible asset is expected to contribute to the cash flows of the Company, an intangible asset is determined to have an indefinite life. Indefinite life intangible assets are not amortized, but tested for impairment annually or more frequently when indicators of impairment exist. If the carrying value of an individual indefinite-lived intangible asset exceeds its fair value, such individual indefinite-life intangible asset is impaired by the amount of the excess.

The estimated useful lives are reviewed at the end of each reporting period, with the effect of any changes in estimate being accounted for on a prospective basis.

Impairment of long-lived assets

The Company reviews long-lived assets, including property and equipment and definite life intangible assets, for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. In order to determine if assets have been impaired, assets are grouped and tested at the lowest

91

level for which identifiable independent cash flows are available (“asset group”). An impairment loss is recognized when the sum of projected undiscounted cash flows is less than the carrying value of the asset group. The measurement of the impairment loss to be recognized is based on the difference between the fair value and the carrying value of the asset group. Fair value can be determined using a market approach, income approach or cost approach. The reversal of impairment losses is prohibited.

Impairment of goodwill and indefinite life intangible assets

Goodwill and indefinite life intangible assets are tested for impairment annually, or more frequently when events or circumstances indicate that impairment may have occurred. As part of the impairment evaluation, the Company may elect to perform an assessment of qualitative factors. If this qualitative assessment indicates that it is more likely than not that the fair value of the indefinite-lived intangible asset or the reporting unit (for goodwill) is less than its carrying value, a quantitative impairment test to compare the fair value to the carrying value. An impairment charge is recorded if the carrying value exceeds the fair value.

Leases

The Company determines if an arrangement is a lease at inception. Operating leases are included in operating lease right‑ of‑ use (“ROU”) assets and accrued obligations under operating lease (current and noncurrent) in the balance sheets. Finance lease ROU assets are included in property and equipment, net and accrued obligations under finance lease (current and non-current) in the balance sheets.

ROU assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent the Company’s obligation to make lease payments arising from the lease. ROU assets are classified as a finance lease or an operating lease. A finance lease is a lease in which 1) ownership of the property transfers to the lessee by the end of the lease term; 2) the lease grants the lessee an option to purchase the underlying asset that the lessee is reasonably certain to exercise; 3) the lease is for a major part of the remaining economic life of the underlying asset; 4) The present value of the sum of the lease payments and any residual value guaranteed by the lessee that is not already included in the lease payments equals or exceeds substantially all of the fair value; or 5) the underlying asset is of such a specialized nature that it is expected to have no alternative use to the lessor at the end of the lease term. The Company classifies a lease as an operating lease when it does not meet any one of these criteria.

ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. As most of the Company’s leases do not provide an implicit rate, the incremental borrowing rate is used based on the information available at commencement date in determining the present value of lease payments. The Company uses the implicit rate when readily determinable. The ROU assets also include any lease payments made and excludes lease incentives. The lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option.

For finance leases, lease expenses are the sum of interest on the lease obligations and amortization of the ROU assets. ROU assets are amortized based on the lesser of the lease term and the useful life of the leased asset according to the property and equipment accounting policy. If ownership of the ROU assets transfers to the Company at the end of the lease term or if the Company is reasonably certain to exercise a purchase option, amortization is calculated using the estimated useful life of the leased asset, according to the property and equipment accounting policy. For operating leases, the lease expenses are generally recognized on a straight-line basis over the lease term and recorded to general and administrative expenses in the statements of net loss and comprehensive loss.

The Company has elected to apply the practical expedient, for each class of underlying asset, except real estate leases, to not separate non-lease components from the associated lease components of the lessee’s contract and account for both components as a single lease component. Additionally, for certain equipment leases, the Company applies a portfolio approach to effectively account for the operating lease ROU assets and liabilities.

The Company has elected not to recognize ROU assets and lease liabilities for short-term leases that have a lease term of 12 months or less that do not include an option to purchase the underlying asset that the Company is reasonably certain to exercise. Short-term leases include real estate and vehicles and are not significant in comparison to the Company’s overall lease portfolio. The Company continues to recognize the lease payments associated with these leases as expenses on a straight-line basis over the lease term.

92

Investments

Debt securities

Debt securities are classified as available-for-sale and are recorded at fair value. Unrealized gains and losses during the year, net of the related tax effect, are excluded from income and reflected in other comprehensive income (loss), and the cumulative effect is reported as a separate component of shareholders’ equity until realized. Debt securities are impaired when a decline in fair value is determined to be other-than-temporary. If the cost of an investment exceeds its fair value, the Company evaluates, among other factors, general market conditions, credit quality of debt instrument issuers, and the duration and extent to which the fair value is less than cost. Once a decline in fair value is determined to be other-than-temporary, an impairment charge is recorded in the statements of net loss and a new cost basis for the investment is established. The Company also evaluates whether there is a plan to sell the security or it is more likely than not that the Company will be required to sell the security before recovery. If neither of the conditions exist, then only the portion of the impairment loss attributable to credit loss is recorded in the statements of net loss and the remaining amount is recorded in other comprehensive income (loss).

Equity investments

Investments in entities over which the Company does not have a controlling financial interest or significant influence are accounted for at fair value. Equity investments without readily determinable fair values are measured at cost with adjustments for observable changes in price or impairments (referred to as the “measurement alternative”). In applying the measurement alternative, the Company performs a qualitative assessment on a quarterly basis and recognizes an impairment if there are sufficient indicators that the fair value of the equity investments are less than carrying values. Changes in value are recorded in other income, net.

Investments in entities over which the Company does not have a controlling financial interest but has significant influence, are accounted for using the equity method, with the Company’s share of earnings or losses reported in earnings or losses from equity method investments on the statements of net loss and comprehensive loss. Equity method investments are recorded at cost, plus the Company’s share of undistributed earnings or losses, and impairment, if any, within Equity method investments on the balance sheets.

The Company assesses investments in equity method investments if there is reason to believe an impairment may have occurred including, but not limited to, ongoing operating losses, projected decreases in earnings, increases in the weighted-average cost of capital, or significant business disruptions. The significant assumptions used to estimate fair value include revenue growth and profitability, capital spending, depreciation and taxes, foreign currency exchange rates, and discount rate. By their nature, these projections and assumptions are uncertain. If it is determined that the current fair value of an equity method investment is less than the carrying value of the investment, the Company will assess if the shortfall is of a temporary or permanent nature and write down the investment to its fair value if it is concluded the impairment is other than temporary.

Assets reclassified from held for sale to held and used

In May 2020, the Company announced its decision to close the High Park Gardens facility in response to its anticipated future product needs and the current economic climate. As a result, the Company adopted an accounting policy for assets held for sale. Assets held for sale are accounted for in accordance with applicable accounting guidance provided in Accounting Standards Codification (“ASC”) Topic 360, Property, Plant and Equipment. The Company classifies its assets as held for sale if, among other criteria, the carrying amount will be recovered principally through a sale transaction rather than continued use and a sale is considered probable and within one year. Assets classified as held for sale are measured at the lower of the carrying amount and fair value less costs to sell. Assets classified as held for sale are combined and presented separately from the other assets in the balance sheets.

In December 2020, upon the Company's determination to discontinue marketing certain assets held for sale, the assets no longer meet the held for sale criteria and are required to be reclassified as held and used at the lower of adjusted carrying value (carrying value of the assets prior to being classified as held for sale adjusted for any depreciation and/or amortization expense that would have been recognized had the assets been continuously classified as held and used) or the fair value at the date of the subsequent decision not to sell. If adjusted carrying value is determined to be lower, a catch-up adjustment for depreciation will be recorded. The depreciation and/or amortization expenses that would have been recognized had the assets been continuously classified as held and used

93

is included as a component of depreciation and amortization expenses in the statements of net loss and comprehensive loss. If fair value is determined to be lower, the Company records a gain or loss included in impairment of assets in the statements of net loss and comprehensive loss.

Fair value measurements

The carrying value of the Company’s accounts receivable, accounts payable, accrued expenses and other current liabilities approximate their fair value due to their short-term nature. Debt securities classified as availablefor-sale are recorded at fair value based on publicly available market information or other estimates determined by management. Equity investments (excluding equity method investments) are recorded at fair value using quoted market prices or broker or dealer quotations, or using the measurement alternative for equity investments without readily determinable fair values. The fair value for equity investments measured using the measurement alternative is determined based on valuation techniques using the best information available, and may include quoted market prices, market comparables, and discounted cash flow projections. Contingent consideration is measured at fair value on a recurring basis based on discounted cash flow projections.

Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. In estimating the fair value of an asset or a liability, the Company takes into account the characteristics of the asset or liability if market participants would take those characteristics into account when pricing the asset or liability at the measurement date.

Convertible notes

The Company accounts for its convertible notes with a cash conversion feature in accordance with ASC 470-20, Debt with Conversion and Other Options (“ASC 470-20”), which requires the liability and equity components of convertible debt instruments that may be settled in cash upon conversion, including partial cash settlement, to be separately accounted for in a manner that reflects the issuer’s nonconvertible debt borrowing rate. The initial proceeds from the sale of convertible notes are allocated between a liability component and an equity component in a manner that reflects interest expense at the rate of similar nonconvertible debt that could have been issued at such time. The equity component represents the excess initial proceeds received over the fair value of the liability component of the notes as of the date of issuance. The resulting debt discount is amortized over the period during which the convertible notes are expected to be outstanding as additional non-cash interest expenses.

Upon repurchase of convertible debt instruments, ASC 470-20 requires the issuer to allocate total settlement consideration, inclusive of transaction costs, amongst the liability and equity components of the instrument based on the fair value of the liability component immediately prior to repurchase. The difference between the settlement consideration allocated to the liability component and the net carrying value of the liability component, including unamortized debt issuance costs, would be recognized as gain (loss) on extinguishment of debt in the statements of net loss and comprehensive loss. The remaining settlement consideration allocated to the equity component would be recognized as a reduction of additional paid-in capital in the balance sheets.

Warrants

In March 2020, the Company closed on a registered offering including Class 2 common stock, warrants, and pre-funded warrants (refer to Note 16). Warrants are accounted for in accordance with applicable accounting guidance provided in ASC Topic 815, Derivatives and Hedging – Contracts in Entity's Own Equity (“ASC 815”), as either liabilities or as equity instruments depending on the specific terms of the warrant agreement. The Company's warrants are classified as liabilities and are recorded at fair value. The warrants are subject to remeasurement at each balance sheet date until settlement and any change in fair value is recognized as a component of change in fair value of warrant liability in the statements of net loss and comprehensive loss. Transaction costs allocated to warrants that are presented as a liability are expensed immediately within other expenses (income) in the statements of net loss and comprehensive loss.

Revenue recognition

Revenue is recognized when control of the promised goods or services, through performance obligations by the Company, is transferred to the customer in an amount that reflects the consideration it expects to be entitled to in exchange for the performance obligations.

94

The Company generates substantially all of its revenue from the sale of cannabis and hemp products through contracts with customers. Cannabis and hemp products are sold through various distribution channels. Revenue is recognized when the control of the goods is transferred to the customer, which occurs at a point in time, typically upon delivery to or receipt by the customer, depending on shipping terms.

Sales taxes collected from customers are remitted to the appropriate taxing jurisdictions and are excluded from sales revenue as the Company considers itself a pass-through conduit for collecting and remitting sales taxes. Excise duties that are both imposed on and concurrent with a specific revenue-producing transaction, that are collected by the Company from a customer are included in revenue. Freight revenues on all product sales, when applicable, are also recognized, on a consistent manner, at a point in time. The term between invoicing and when payment is due is not significant and the period between when the entity transfers the promised good or service to the customer and when the customer pays for that good or service is one year or less.

The Company considers whether there are other promises in the contracts that are separate performance obligations to which a portion of the transaction price needs to be allocated. In determining the transaction price for the sale of goods, the Company considers the effects of variable consideration and the existence of significant financing components (if any).

Some contracts for the sale of goods may provide customers with a right of return, volume discount, bonuses for volume/quality achievement, or sales allowance. In addition, the Company may provide in certain circumstances, a retrospective price reduction to a customer based primarily on inventory movement. These items give rise to variable consideration. The Company uses the expected value method to estimate the variable consideration because this method best predicts the amount of variable consideration to which the Company will be entitled. The Company uses historical evidence, current information and forecasts to estimate the variable consideration. The requirements in ASC 606 on constraining estimates of variable consideration are applied to determine the amount of variable consideration that can be included in the transaction price. The Company reduces revenue and recognizes a contract liability equal to the amount expected to be refunded to the customer in the form of a future rebate or credit for a retrospective price reduction, representing its obligation to return the customer’s consideration. The estimate is updated at each reporting period date.

The Company may receive short-term advances from its customers. Using the practical expedient in ASC 606, the Company does not adjust the promised amount of consideration for the effects of a significant financing component if the Company expects, at contract inception, that the period between when the Company transfers a promised good to a customer and when the customer pays for that good or service will be one year or less. The Company has not, nor expects to receive long-term advances from customers.

Cost of sales

Cost of sales represents costs directly related to manufacturing and distribution of the Company’s products. Primary costs include raw materials, packaging, direct labor, overhead, shipping and handling, the depreciation of manufacturing equipment and production facilities, and excise taxes and tarrifs. Manufacturing overhead and related expenses include salaries, wages, employee benefits, utilities, maintenance and property taxes. Cost of sales also includes inventory valuation adjustments. The Company recognizes the cost of sales as the associated revenues are recognized.

General and administrative expenses

General and administrative expenses are comprised primarily of (i) personnel related costs such as salaries, benefits, annual employee bonus expense and stock-based ‘compensation costs for personnel in corporate, finance, legal, and other administrative positions; (ii) legal, accounting and other professional fees; (iii) corporate insurance and other facilities costs associated with our corporate and administrative locations; depreciation and amortization expenses associated with our corporate assets, and (iv) severance and other costs associated with headcount reductions.

Sales and marketing expenses

Sales and marketing expenses are comprised primarily of (i) personnel related costs such as salaries, benefits, annual employee bonus expense and stock-based compensation costs for personnel in sales and marketing, (ii) commissions paid to our third-party workforce, and (iii) marketing and advertising expenses. Advertising costs

95

are expensed as incurred and were $2,384, $3,563 and $618 the years ended December 31, 2020, 2019 and 2018, respectively.

Research and development expenses

Research and development expenses are comprised primarily of costs for personnel, including salaries, benefits, employee bonus, stock-based compensation; clinical study costs; contracted research; consulting services; materials and supplies; milestones; an allocation of our occupancy costs; and other expenses incurred to sustain our overall research and development programs.

Stock-based compensation

The Company measures and recognizes compensation expense for stock options and RSUs to employees and non-employees on a straight-line basis over the vesting period based on their grant date fair values. The Company estimates the fair value of stock options on the date of grant using the Black-Scholes option pricing model.

The fair value of RSUs is based on the share price as at date of grant. For stock options and RSUs granted in 2018, prior to the Company’s initial public offering, the fair value of common stock at the date of grant was determined by the Board of Directors with assistance from third-party valuation specialists. The Company estimates forfeitures at the time of grant and revises these estimates in subsequent periods if actual forfeitures differ from those estimates.

For performance-based stock options and RSUs, the Company records compensation expense over the estimated service period adjusted for a probability factor of achieving the performance-based milestones. At each reporting date, the Company assesses the probability factor and records compensation expense accordingly, net of estimated forfeitures.

Fully vested, non-forfeitable equity instruments issued to parties other than employees are measured on the date they are issued where there is no specific performance required by the grantee to retain those equity instruments. Stock-based payment transactions with non-employees are measured at the fair value of the consideration received or the fair value of the equity instruments issued, whichever is more reliably measurable. Where fully vested, non-forfeitable equity instruments are granted to parties other than employees in exchange for notes or financing receivable, the note or receivable is presented in additional paid-in capital on the balance sheets.

Income taxes

The Company uses the asset and liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on the differences between the financial reporting and the tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. Management makes an assessment of the likelihood that the resulting deferred tax assets will be realized. A valuation allowance is provided when it is more likely than not that some portion or all of a deferred tax asset will not be realized.

The Company recognizes uncertain income tax positions at the largest amount that is more likely than not to be sustained upon audit by the relevant taxing authority. An uncertain income tax position will not be recognized if it has less than a 50% likelihood of being sustained. Changes in recognition or measurement are reflected in the period in which judgment occurs.

New accounting pronouncements not yet adopted

In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740) - Simplifying the Accounting for Income Taxes (“ASU 2019-12”), which is intended to simplify various aspects related to accounting for income taxes. ASU 2019-12 removes certain exceptions to the general principles in Topic 740 and also clarifies and amends existing guidance to improve consistent application. The standard is effective for annual reporting periods beginning after December 15, 2021 and including interim periods within those fiscal years, which means that it will be effective for the Company in the first quarter of our year beginning January 1, 2021. The Company is currently evaluating the effect of adopting this ASU on the Company’s financial Statements. We do not expect the adoption of ASU 2016-12 to have a material impact on our consolidated financial statements.

96

In January 2020, the FASB issued ASU 2020-01, Investments - Equity Securities (Topic 321), Investments - Equity Method and Joint Ventures (Topic 323), and Derivatives and Hedging (Topic 815) (“ASU 2020-01”), which is intended to clarify the interaction of the accounting for equity securities under Topic 321 and investments accounted for under the equity method of accounting in Topic 323 and the accounting for certain forward contracts and purchased options accounted for under Topic 815. ASU 2020-01 is effective for the Company beginning January 1, 2021. The Company is currently evaluating the effect of adopting this ASU.

In August 2020, the FASB issued ASU 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity (“ASU 2020-06”), which is intended to address issues identified as a result of the complexity associated with applying generally accepted accounting principles (GAAP) for certain financial instruments with characteristics of liabilities and equity. ASU 2020-06 is effective for the Company beginning January 1, 2022. The Company is currently evaluating the effect of adopting this ASU.

In October 2020, the FASB issued ASU 2020-09, Debt (Topic 470): Amendments to SEC Paragraphs Pursuant to SEC Release No. 33-10762 (“ASU 2020-09”), which amends and supersedes various SEC paragraphs pursuant to the issuance of SEC Final Rule Release No. 33-10762, Financial Disclosures about Guarantors and Issuers of Guaranteed Securities and Affiliates Whose Securities Collateralize a Registrant's Securities. ASU 202009 is effective for the Company beginning January 4, 2021. The Company is currently evaluating the effect of adopting this ASU.

3. Assets Reclassified from Held for Sale to Held and Used

On May 26, 2020, the Company announced its decision to close its High Park Gardens Facility, a whollyowned subsidiary of the Company based in Leamington, Ontario in response to its anticipated future product needs and the current economic climate. At that time, the Company concluded that the assets attributable to High Park Gardens met the criteria for classification as assets held for sale and that the closure did not represent a strategic shift that would have a major impact on the Company’s business plan or its primary markets, and therefore did not qualify as a discontinued operation.

As a result of the Company’s decision to close this facility, the Company recognized impairment charges of $25,051 recorded to impairment of assets within the statements of net loss and comprehensive loss to adjust the fair value, less costs to sell, of the assets classified as held for sale. This included impairment charges of $13,616 relating to land and buildings, $10,239 relating to the write-down to nil of its cultivation license (refer to Note 11) and $1,196 relating to foreign currency translation adjustments.

On December 16, 2020, the Company made a decision to discontinue marketing the High Park Gardens Facility and to retain the disposal group for future operations. The Company reclassified the assets to held and used measured at fair value in the Company’s cannabis segment. When the Company reclassified the assets of the High Park Gardens facility to held and used, the Company recognized additional impairment charges of $2,875 relating to land and buildings recorded to impairment of assets within the statements of net loss and comprehensive loss to adjust to the fair values of the respective assets.

No assets were classified as held for sale as of December 31, 2020 or December 31, 2019.

4. ABG Profit Participation Arrangement

On January 24, 2020, the Company entered into (i) an Amended and Restated Profit Participation Agreement (the “A&R Profit Participation Agreement”) with ABG, which amended and restated in its entirety the Profit Participation Agreement, dated January 14, 2019, and (ii) the First Amendment to Payment Agreement with ABG (the “Payment Agreement Amendment”), which amends the Payment Agreement, dated January 14, 2019. The Company and ABG agreed that Tilray no longer has any obligation to pay the additional consideration with an aggregate value of $83,333 in cash or in shares of Class 2 common stock. In addition, the Company is not entitled to any guaranteed minimum participation rights and beginning January 1, 2020 through December 31, 2028, the Company agreed that it is not entitled to any participation rights until such participation rights with respect to each contract year exceeds $10,000, and in the event the participation rights thresholds are achieved, the Company is entitled to the full 49% participation rights.

97

As a result of entering into the A&R Profit Participation Agreement and the Payment Agreement Amendment, the Company derecognized the ABG finance receivable, $7,011 of which was recorded to impairment of assets through the statements of net loss and comprehensive loss and $28,900 of which was recorded through accumulated deficit in January 2020.

The Company entered into a Trademark License Agreement with ABG on April 1, 2019 for the use of the Prince trademark (“ABG Prince Agreement”). Under the ABG Prince Agreement, the Company pays a royalty on actual product sales in addition to a guaranteed minimum royalty payment (“GMR”) of $500 on April 1, 2019, October 1, 2019, January 1, 2020 and July 1, 2020, with subsequent quarterly payments of $375 commencing January 1, 2021 until the maturity date of December 31, 2025.

5. Inventory

Inventory is comprised of the following items:

Inventory is comprised of the following items:
	December 31,
	2020	2019
Raw materials	$ 15,223	$ 15,926
Work-in-process	61,867	53,973
Finishedgoods	16,555	17,962
Total	$ 93,645	$ 87,861

Inventory is written down for any obsolescence, spoilage and excess inventory or when the net realizable value of inventory is less than the carrying value. During the year ended December 31, 2020, the Company recorded charges for inventory and inventory-related write downs as a component of cost of sales. Cannabis products were written down by $24,288 and hemp products were written down by $4,040 (2019: $49,378 and $3,880).

Included in the inventory-related write downs in the cannabis segment are write downs of $4,934 resulted from a loss on deposit payments for future purchases of inventory to secure supply (refer to Note 6) and $5,157 of additional termination penalties to the same supplier.

6. Prepayments and Other Current Assets

Prepayments and other current assets are comprised of the following items:

	December 31,	December 31,
	2020	2019
Deposits	$ 15,976	$ 25,490
Taxes receivable	12,122	6,165
Prepayments	6,542	5,847
ABG finance receivable - current	—	671
Total	$ 34,640	$ 38,173

Deposits include advance payments on future purchases of inventory to secure supply. During the year ended December 31, 2020, the Company reached agreement with certain suppliers to terminate supply agreements. As a result, deposits have been written down by $4,934 in the Cannabis segment and were recorded in cost of sales in the statements of net loss and comprehensive loss (refer to Note 5).

98

7. Investments

Other investments

Long-term investments are comprised of the following items:

Long-term investments are comprised of the following items:
	December 31, 2020	December 31, 2019
Equityinvestments measured at fair value	$ 477	$ 4,183
Equityinvestments under measurement alternative	11,392	14,954
Debt securities classified under available-for-sale method	2,500	5,047
Total other investments	$ 14,369	$ 24,184

The Company’s equity investments at fair value consist of publicly traded shares and warrants held by the Company. The Company’s equity investments under measurement alternative include equity investments without readily determinable fair values. At December 31, 2020 the Company’s debt securities under available-for-sale method consists of a convertible debt instrument with an interest rate of 10% and with contractual maturity in 2022. The Company has negotiated a settlement of this instrument with the lender prior to its contractual maturity for $2,500 due in February 2021, as such the instrument is held at the expected settlement value as of December 31, 2020.

For the year ended December 31, 2020, there was $2,440 (2019- $0) realized loss recognized related to equity investments at fair value. Unrealized losses recognized in other income, net during the year ended December 31, 2020 on equity investments still held at December 31, 2020 is $4,283 (2019 - $939). During 2020 an equity investment under the measurement alternative became publicly traded and its remaining shares are now held as an equity method investment measured at fair value which contributed to unrealized losses during the period.

Equity method investments

On December 31, 2018, the Company entered into a joint venture with Anheuser-Busch InBev (“AB InBev”) to research and develop non-alcohol beverages containing cannabis. Under the terms of the arrangement, the Company and AB InBev each have 50% ownership and 50% voting interest in the Plain Vanilla Research Limited Partnership (“Fluent”), headquartered in Canada. The Company has determined that Fluent is a VIE, but the Company is not the primary beneficiary as the Company does not have the power to direct the activities of the VIE that most significantly impact the VIE’s economic performance. Accordingly, the Company does not consolidate the financial statements of Fluent and accounts for this investment using the equity method of accounting. At the date of initial investment there was no difference in the carrying value of the investment and the proportional interest in the underlying equity in the net assets of Fluent. At December 31, 2020 the maximum exposure to loss is limited to the Company’s equity investment in the joint venture.

The Company has made capital contributions of $3,764 (2019 - $12,000, 2018 - $0) to Fluent during the year ended December 31, 2020. In addition, the Company had purchased $4,300 of equipment which was subsequently sold to Fluent at the net book value of $4,300 during the year ended December 31, 2019.

The Company provides production support services to Fluent on a cost recovery basis. During the year ended December 31, 2020, total fees charged were $4,113 (2019 - $388). Total amounts included in accounts payable is $674 at Dec 31, 2020 (December 31, 2019 - $388).

On September 19, 2019, the Company entered into a joint venture with Cannfections Group Inc. (“Cannfections”) to develop and manufacture confectionary cannabis products. Under the terms of the arrangement, the Company and Cannfections each have 50% ownership and 50% voting interest. At the date of initial investment, there was no difference in the carrying value of the investment and the proportional interest in the underlying equity in the net assets of Cannfections. During the year ended December 31, 2020 the company incurred $436 in expenses for purchases from Cannfections (2019 - $84). During the year ended December 31, 2020 the Company made no contributions to the joint venture. During the year ended December 31, 2019, the Company contributed $3,600 to the joint venture, consisting of $1,901 of cash and $1,699 of Class 2 common stock.

99

The Company’s ownership interests in its equity method investments as of December 31, 2020 and 2019 were as follows:

were as follows:
	Approximate	Carrying value		Loss from equity method investments Year ended
	ownership %	December 31, 2020		December 31, 2020
Investment in Fluent	50%	$ 5,291		$ (6,253 )
Investment in Cannfections	50%	4,009		270
Total equity method investments		$ 9,300		$ (5,983 )
		Carrying value		Loss from equity method investments
	Approximate			Year ended
	ownership %	December 31, 2019		December 31, 2019
Investment in Fluent	50%	$	7,836	$ (4,437 )
Investment in Cannfections	50%		3,612	(67 )
Total equity method investments		$	11,448	$ (4,504 )
Summary financial information for the equity method investments		on	an aggregated basis was as follows:
			December 31, 2020 December 31, 2019
Current assets			$ 12,644 $ 13,942
Non current assets			$ 6,608 $ 4,987
Current liabilities			$ 5,663 $ 1,561
Non current liabilities			$ — $ —
			Year ended Year ended
			December 31, 2020 December 31, 2019
Revenues			$ 5,844 $ 113
Grossprofit			$ 2,118 $ 78
Net loss			$ (11,966 ) $ (9,008 )
8. Accounts Receivable and Allowance for Credit Losses The Company maintains an allowance for credit losses at an amount sufficient to absorb losses inherent in the existing accounts receivable portfolio as of the reporting dates based on the estimate of expected net credit losses. The following table provides activity in the allowance for credit losses for the year ended December 31, 2020:
Allowance for credit losses,January1,2020					$ 615
Provision for expected credit losses(1)					401
Write-offs charged against allowance					(163 )
Recoveries of amountspreviouslywritten off					—
Foreign currencytranslation adjustment					34
Allowance for credit losses, December 31, 2020					$ 887
Accounts receivable balance before allowance for credit losses and provision for sales returns, December 31, 2020					$ 31,571

(1) The provision for expected credit losses is recorded in general and administrative expenses.

100

9. Property and Equipment, Net

Property and equipment, net consisted of the following:

Property and equipment, net consisted of the following:
	December 31,
	2020	2019
Land	$ 6,771	$ 6,417
Buildings and leasehold improvements	117,325	109,172
Laboratoryand manufacturingequipment	37,176	31,173
Office and computer equipment	1,710	2,659
ROU assets under finance lease	15,072	14,753
Construction-in-process	49,380	37,160
	227,434	201,334
Less: accumulated depreciation	(27,875 )	(17,117 )
Total	$ 199,559	$ 184,217

For the year ended December 31, 2020, total depreciation on property and equipment was $12,508 (2019 – $9,282 and 2018 – $3,410). Depreciation expenses included in cost of sales relating to manufacturing equipment and production facilities for the year ended December 31, 2020 is $4,932 (2019 – $4,242 and 2018 – $1,964). Depreciation expenses related to general office space and equipment of $2,720 (2019 – $1,783, 2018 - $149) is included in depreciation and amortization expenses. The remaining depreciation is capitalized in the cost of inventory.

The Company had $44,644 in property and equipment additions during the year ended December 31, 2020 (2019 – $119,184 and 2018 – $44,451). No non-cash finance lease assets were added in 2020 (2019 – $4,617 and 2018 – $114) and for the year ended December 31, 2020, there is $2,467 (2019 – $652 and 2018 – $158) of capitalized interest included in construction-in-progress.

Additions to construction-in-process primarily relate to the ongoing construction of the Company’s Portugal facilities.

10. Leases

The Company has operating and finance leases for facilities and certain equipment. Operating and finance leases have remaining weighted-average remaining lease terms of 7 years and 2 years, respectively, as at December 31, 2020, some of which include options to extend the leases for up to 10 years and some of which include options to terminate the leases within 1 year.

The table below presents the lease-related assets and liabilities recorded on the balance sheet.

	December 31,	December 31,
Classifications on the Balance Sheet	2020	2019
Assets
Operatinglease assets Operatinglease,right-of-use assets	$ 17,985	$ 17,514
Finance lease assets Propertyand equipment,net	13,167	13,307
Total lease assets	$ 31,152	$ 30,821
Liabilities
Current
Operating Accrued lease obligations - current	$ 2,913	$ 2,473
Finance Accrued lease obligations - current	—	—
Noncurrent
Operating Accrued lease obligations - Noncurrent	15,346	15,255
Finance Accrued lease obligations - Noncurrent	15,277	14,152
Total lease liabilities	$ 33,536	$ 31,880

101

Weighted-average remaininglease term
Operatingleases	7	9
Finance leases	2	4
Weighted-average discount rate
Operatingleases	4.98 %	5.73 %
Finance leases	10.75 %	8.42 %

The table below presents certain information related to the lease costs for finance and operating leases.

	December 31,	December 31,
	2020	2019
Finance lease cost
Amortization of ROU assets	$ 326	$ 588
Interest on lease liabilities	1,435	370
Operatinglease expenses(1)	4,065	2,519
Short term lease expenses(1)	9	256
Sublease income(2)	(486 )	(230 )
Total lease expenses	$ 5,349	$ 3,503

(1) Included in cost of goods sold and general and administrative expenses

(2) Included in other income, net

The table below presents supplemental cash flow information related to leases.

	December 31, December 31,
	2020 2019
Cashpaid for amounts included in the measurement of lease liabilities:
Operatingcash flows from operatingleases	3,810 2,312
Operatingcash flows from finance leases	999 336
Financingcash flows from finance leases	— 504
Non-cash additions to ROU assets and lease liabilities:
Operatingleases	423 16,043
Finance leases	$ — $ 4,617

Lease commitments

The Company leases various facilities, under non-cancelable finance and operating leases, which expire at various dates through September 2027.

Maturities of lease liabilities:

Maturities of lease liabilities:
Year ending December 31,	Operating Leases	Finance Leases
2021	$ 3,792	$ 1,051
2022	3,436	5,960
2023	3,290	12,438
2024	2,704
2025	2,151	—
Thereafter	6,401	—
Total minimum leasepayments	21,774	19,449
Less: amounts of leases related to interestpayments	3,515	4,172
Present value of minimum leasepayments	18,259	15,277
Less: current accrued lease obligation	2,913	—
Obligations recognized	$ 15,346	$ 15,277

102

11. Intangible Assets

Intangible assets are comprised of the following items:

							December 31,	December 31,
				2	020					2019
	Weighted Average Amortization Period (inyears)					Impairment	Net			Accumulated Amortization		Net
				Accumulated
		Cost		Amortization				Cost			Impairment
Definite-lived intangible assets:
Patent	—	$ 669		$ 131		$ 538	$ —	$ 716		$ 99	$ —	$ 617
Customer relationships	16	138,885		16,030		—	122,855	135,953		7,132	—	128,821
Developed technology	10	7,227		1,325		—	5,902	7,074		590	—	6,484
Websites	3	5,332		4,348		—	984	5,157		3,331	—	1,826
Trademarks and licenses	5	9,009		1,245		7,650	114	9,135		925	—	8,210
Total		161,122		23,079		8,188	129,855	158,035		12,077	—	145,958
Indefinite-lived intangible assets:
Cultivation license	—	10,239		—		10,239	—	10,689		—	—	10,689
Alef license	—	—		—		—	—	4,086		—	4,086	—
Trademarks	Indefinite	56,590		—		—	56,590	55,416		—	—	55,416
Rights under ABG Profit	—	16,765		—		16,765	—	119,366		—	102,601	16,765
Participation Arrangement
Total		83,594		—		27,004	56,590	189,557		—	106,687	82,870
Total intangible assets		$ 244,716		$ 23,079		$ 35,192	$ 186,445	$ 347,592		$ 12,077	$ 106,687	$ 228,828

In connection with the Company’s closure of its High Park Gardens facility, the Company determined that the fair value of the indefinite-lived cultivation license was below carrying value. As a result, the Company incurred non-cash impairment charges of $10,239, representing the full net book value of the cultivation license, presented in impairment of assets in the statements of net loss and comprehensive loss (refer to Note 3).

In connection with the decreased demand projections of CBD products in the United States resulting in a reduced estimate of future cash flows, during the first quarter of 2020 the Company determined that the fair value of indefinite-lived rights under the ABG Profit Participation Arrangement and definite-lived trademarks under the Trademark and License Agreement with ABG for the use of the Prince trademark (“ABG Prince Agreement”) were below the carrying value. As a result, the Company incurred non-cash impairment charges of $16,765 and $6,063 representing the full net book values of the intangible assets relating to the ABG Profit Participation Agreement and ABG Prince Agreement respectively, presented in impairment of assets in the statements of net loss and comprehensive loss (refer to Note 4). In June 2020, the Company completed the separation from Smith & Sinclair and recognized additional non-cash impairment charges of $3,320 presented in impairment of assets in the statement of net loss and comprehensive loss, of which $2,126 related to other CBD trademarks and patents.

Amortization expenses for intangibles was $11,002, $9,824, and $374 in 2020, 2019, and 2018, respectively. Expected future amortization expenses for intangible assets as of December 31, 2020 are as follows: 2021 – $10,222; 2022 – $9,744; 2023 - $9,500; 2024 - $9,493, 2025 – $9,469; and thereafter – $81,427.

12. Goodwill

The following table shows the change in carrying amount of goodwill:

	Hemp	Cannabis	Total
Goodwill - January1,2020	$ 133,314	$ 29,937	$ 163,251
Foreign currencytranslation adjustment	3,018	646	3,664
Goodwill - December 31, 2020	$ 136,332	$ 30,583	$ 166,915

Goodwill is tested for impairment annually, or more frequently when events or circumstances indicate that impairment may have occurred. At December 31, 2020, the Company determined the hemp reporting unit, representing $136,332 of the $166,915 total goodwill, was at risk of having a carrying value exceeding the fair value. As a result, a quantitative test was performed to determine if impairment exists. In performing the Company’s impairment analysis at December 31, 2020, the fair value of the hemp reporting unit was determined primarily by discounting estimated future cash flow, which were determined based on revenue and expense growth assumptions ranging from 16% to 40%, at a weighted average cost of capital (discount rate) ranging from 10% to 12%. The discounted future cash flow model also makes the key assumption that CBD revenue will commence to build in the third quarter of 2021. The fair value of the hemp reporting unit was determined to exceed the carrying value by

103

$117,500, or 38%, and no impairment was recorded. A relatively small change in the underlying assumptions, including a 1% change in the weighted average cost of capital, continued lack of clarity from the Food and Drug Administration regarding approval of CBD or the financial performance of the reporting unit in future years may cause a change in the results of the impairment assessment in future periods and, as such, could result in an impairment of goodwill.

13. Accounts Payable, Accrued Expenses and Other Current Liabilities

Accounts payable, accrued expenses and other current liabilities are comprised of the following items:

	December 31,	December 31,
	2020	2019
Other accrued expenses and current liabilities	$ 24,181	$ 17,032
Accruedpayroll and employment related withholdingtaxes	9,282	24,765
Accrued interest on convertible notes	3,473	5,938
ABG finance liability- current	1,500	1,500
Accrued legal andprofessional fees	1,091	1,174
Accrued interest on Senior Facility	419	—
Contingent consideration for acquisitions	—	420
Total accrued expenses and other current liabilities	$ 39,946	$ 50,829

During the year ended December 31, 2020, the Company reduced its employee headcount in portions of its global organization to meet the needs of the current industry environment. During the year ended December 31, 2020, the Company incurred $4,864 (2019 – $0) in severance costs, of which $4,321 and $543 is included in salaries within general and administrative expenses and in cost of sales, respectively. During the year ended December 31, 2020, severance costs of $3,205 are allocated to the cannabis reportable segment and $1,659 are allocated to the hemp reportable segment. Management continues to evaluate its cost structure and may take further actions in the future and incur additional related costs. The following table shows the reconciliation of the severance costs included within the accrued payroll and employment related withholding taxes balance above, relating to scheduled benefit payments which were communicated to employees prior to December 31, 2020:

OpeningBalance as of January1,2020	$ —
Additional charges	4,864
Lesspayments made to employees	4,219
Closing Balance as of December 31, 2020	$ 645

14. Convertible Notes

In October 2018 the Company issued convertible notes with a face value of $475,000. The net proceeds from the offering were approximately $460,134, after deducting commissions and other fees incurred.

The convertible notes bear interest at a rate of 5.00% per annum, payable semi-annually in arrears on April 1 and October 1 of each year, beginning on April 1, 2019. Additional interest may accrue on the convertible notes in specified circumstances. The convertible notes will mature on October 1, 2023, unless earlier repurchased, redeemed or converted. There are no principal payments required over the five year term of the convertible notes, except in the case of redemption or events of defaults.

The convertible notes are governed by an Indenture between the Company, as issuer, and GLAS Trust Company LLC, as trustee. The convertible notes are the Company’s general unsecured obligations and rank senior in right of payment to all of the Company’s indebtedness that is expressly subordinated in right of payment to the notes; equal in right of payment with any of the Company’s unsecured indebtedness that is not so subordinated; effectively junior in right of payment to any of Company’s secured indebtedness to the extent of the value of the assets securing such indebtedness; and structurally junior to all indebtedness and other liabilities (including trade payables but excluding intercompany obligations) of the Company’s current or future subsidiaries.

104

The Indenture includes customary covenants and sets forth certain events of default after which the convertible notes may be declared immediately due and payable, including certain types of bankruptcy or insolvency involving the Company.

To the extent the Company so elects, the sole remedy for an event of default relating to certain failures by the Company to comply with certain reporting covenants in the Indenture will, for the first 365 days after such event of default, consist exclusively of the right to receive additional interest on the notes. Upon conversion, the Company will pay or deliver, as the case may be, cash, shares of our common stock or a combination of cash and shares of the Company’s common stock, at the Company’s election (the “cash conversion option”). The initial conversion rate for the convertible notes is 5.9735 shares of common stock per one thousand dollar principal amount of notes, which is equivalent to an initial conversion price of approximately $167.41 per share of common stock, which represents approximately 1,660 shares of common stock, based on the $277,857 aggregate principal amount of convertible notes outstanding as of December 31, 2020. Throughout the term of the convertible notes, the conversion rate may be adjusted upon the occurrence of certain events.

Prior to the close of business on the business day immediately preceding April 1, 2023, the convertible notes will be convertible only under the specified circumstances. On or after April 1, 2023 until the close of business on the business day immediately preceding the maturity date, holders may convert all or any portion of their convertible notes, in multiples of one thousand dollar principal amount, at the option of the holder regardless of the forementioned circumstances.

As a result of the cash conversion option, the Company separately accounts for the value of the embedded conversion option as a component of equity. The value of the embedded conversion option is the residual of the net proceeds of the issuance, less the estimated fair value of the debt without the conversion feature, and amounted to $57,595 at issuance. The estimated fair value of the debt without the conversion feature, was determined using the expected cash flows of the convertible notes discounted by the estimated interest rate of similar nonconvertible debt; the debt discount is being amortized as additional non-cash interest expenses over the term of the convertible notes using the interest method with an effective interest rate of 8% per annum. The equity component is not remeasured as long as it continues to meet the conditions for equity classification.

The Company may from time to time seek to retire or purchase its convertible notes, in open market purchases, privately negotiated transactions or otherwise. Such purchases or exchanges, if any, will depend on prevailing market conditions, the company's liquidity requirements, contractual restrictions and other factors. The amounts involved in any such transactions, individually or in the aggregate, may be material. During November 2020, the Company entered into two privately negotiated exchange agreements (the “Exchange Agreements”) with certain holders of our convertible notes. Under the terms of the Exchange Agreements, the holders agreed to exchange an aggregate principal amount of approximately $197,143 of convertible notes plus accrued interest held by them in exchange for an aggregate of 17,339,577 shares of our Class 2 common stock. Effectively, we agreed to repurchase a portion of our Notes at discounts of 36% and 42%, respectively, to their face value, using shares issued at our most recent closing market price on November 20, 2020 and November 23, 2020 (which is equivalent to a conversion price of $7.36 per share and $6.68 per share, respectively).

In accordance with ASC 470-20, Convertible Debt, the Company utilized the inducement method of accounting to record the early retirement of the convertible debt in the two-step approach for induced conversions resulting in a net gain on debt conversion of $61,118 which the Company recorded on its Statement of Net Loss and Comprehensive Loss. In the first step, we assessed a loss on extinguishment using the fair value of the converted debt, less the fair value of the debt under the original terms, resulting in a loss on induced conversion of $114,891. In the second step, we assessed a gain on conversion, as the fair value of the converted debt given up at inducement exceeded the fair value of the shares issued to the converted holders resulting in a gain on extinguishment of debt of $176,009.

As of December 31, 2020, the convertible notes are not yet convertible. The convertible notes will become convertible upon the satisfaction of the above circumstances. In accounting for the transaction costs related to the issuance of the convertible notes, the Company allocated the total amount of offering costs incurred to the debt and equity components based on their relative values. Transaction costs attributable to the convertible notes totaling $13,467, are being amortized as non-cash interest expenses over the term of the convertible notes, and offering costs attributable to the equity component, totaling $1,398, were recorded within stockholders’ equity (deficit). The remaining unamortized debt discount related to the convertible notes of $15,229 as of December 31, 2020 will be accreted over the remaining term of the convertible notes, which is approximately 33 months.

105

As at December 31, 2020, the Company was in compliance with all the covenants set forth under the Indenture.

The following table sets forth the net carrying amount of the convertible notes:

	December 31, 2020	December 31, 2019
5.00% convertible notes	$ 277,857	$ 475,000
Unamortized discount	(15,229 )	(34,219 )
Unamortized transaction costs	(4,839 )	(10,571 )
Net carrying amount	$ 257,789	$ 430,210

The following table sets forth total interest expenses recognized related to the convertible notes:

	Year Ended December 31,	Year Ended December 31,	Year Ended December 31,
	2020	2019	2018
Contractual coupon interest	$ 22,929	$ 23,750	$ 5,302
Amortization of discount	7,863	7,468	2,152
Amortization of direct issue costs	2,454	2,375	28
Total	$ 33,246	$ 33,593	$ 7,482

15. Senior Facility

On February 28, 2020, High Park Holdings Ltd., a wholly owned subsidiary of the Company (the “Borrower”) entered into a credit agreement, denominated in Canadian dollars (“C$”), for a senior secured credit facility in a maximum aggregate principal amount of $59,600 (C$79,800) (the “Senior Facility”). An aggregate principal amount equal to $49,700 (C$66,500) was drawn on February 28, 2020 (the “Closing Date Draw”) and the Company submitted an irrevocable 30 day notice on May 4, 2020 to draw an additional $9,900 (C$13,300) (the “Additional Draw”).

On June 5, 2020, as a result of COVID-19 related financial markets conditions that affected the lender of the Senior Facility, and not because of any material changes to the business of Tilray or its subsidiaries, the lender requested that Tilray withdraw its outstanding request for the Additional Draw of $9,900 (C$13,300) under the Senior Facility. In exchange for the Company’s accommodation of the lender’s request to withdraw its funding request, the lender agreed to enter into the First Amendment of the Senior Facility (the “Amendment”). The Amendment provides for interest-only payments for the remainder of its term with all outstanding principal payments due at February 28, 2022. This will result in an aggregate balance of $47,355 (C$64,283) due at February 28, 2022. Additionally, and at such time as the lender’s business may allow, the lender may make the additional proceeds of $9,900 (C$13,300) available, at its sole discretion.

The Senior Facility bears interest on the outstanding principal balance at an annual rate equal to the Canadian prime rate plus 8.05%, calculated based on the daily outstanding balance of the Senior Facility calculated and compounded monthly in arrears and with no deemed reinvestment of monthly payments. Interest is due monthly throughout the term. The Company has the option to voluntarily prepay, without penalty, the outstanding amounts, in full or in part, at any time starting 6 months from the closing date subsequent to providing 75 days’ notice.

Transaction costs incurred on the Closing Date Draw were $3,306 (C$4,425). There were no fees incurred associated with the Amendment. Transaction costs are deferred and amortized as a component of interest expense over the estimated term using the effective interest rate method. On June 29, 2020, the lender notified the Company that it had exercised its unilateral right to syndicate $19,153 (C$26,000) of the Company’s Senior Facility in the aggregate principal amount of $59,600 (C$79,800). The Senior Facility’s terms otherwise remain unchanged.

The Senior Facility has first priority claims on all North American assets of the Company and contains certain affirmative and negative covenants. The operational covenant includes a minimum unrestricted cash threshold of $29,466 (C$40,000) in order for the Company to make additional capital expenditures and investments. The Senior Facility is collateralized against all real and personal property owned, leased and operated by the Company in North America, and any and all other property of the Company now existing and acquired in North America after the closing date. As of December 31, 2020, the Company was in compliance with all covenants set forth under the Senior Facility.

106

The following table sets forth the net carrying amount of the Senior Facility:

The following table sets forth the net carrying amount of the Senior Facility:
	December 31, 2020
Senior Facility	$ 50,498
Unamortized transaction costs	(2,028 )
Net carryingamount	48,470
Less: currentportion of Senior Facility	—
Total noncurrent portion of Senior Facility	$ 48,470

The following table sets forth total interest expense recognized related to the Senior Facility:

The following table sets forth total interest expense recognized related to the Senior	Facility:
	Year ended December 31,
	2020
Contractual interest at Canadianprimeplus 8.05%	$ 4,257
Amortization of transaction costs	1,372
Total	$ 5,629

16. Registered Offering and Warrants

On March 17, 2020, the Company closed a registered offering of 7,250,000 shares of the Company’s Class 2 common stock for $4.76 per share with an equal number of accompanying warrants and 11,750,000 pre-funded warrants for $4.7599 (the “pre-funded warrants”) with an equal number of accompanying warrants. The pre-funded warrants had an exercise price per share of Class 2 common stock of $0.0001 and were exercisable at any time after their original issuance and expire on the fifth anniversary date of issuance. As of December 31, 2020, all pre-funded warrants have been exercised. The 19,000,000 total accompanying warrants (the “warrants”) allow the holders to purchase an aggregate of 19,000,000 shares of the Company’s Class 2 common stock. The warrants have an exercise price per share of Class 2 common stock of $5.95 and are exercisable at any time after the first trading day following the six-month anniversary of the issuance and will expire on the fifth anniversary date from the date they become exercisable. As of December 31, 2020, the warrants remain outstanding.

The total gross proceeds of the registered offering were $90,439, of which $21,025 was allocated to the Class 2 common stock at the offering close and $69,414 was allocated to the warrant liability. Issuance costs incurred on the registered offering were $5,150, of which $3,953 was recorded to other expenses (income) in the statements of net loss and comprehensive loss and $1,197 was allocated to the Class 2 common stock and recorded net against the allocated gross proceeds in additional paid-in-capital.

The warrants contain anti-dilution price protection features, which adjust the exercise price of the warrants if the Company subsequently issues Class 2 common stock at a price lower than the exercise price of the warrants. In the event additional warrants or convertible debt are issued with a lower and/or variable exercise price, the exercise price of the warrants will be adjusted accordingly. There were no triggering events during the year ended December 31, 2020. The Company received stockholder approval of the anti-dilution price protection feature at the Company’s Annual Meeting on May 28, 2020.

The Company's warrants are classified as liabilities as they are to be settled in registered shares, and the registration statement is required to be active, unless such shares may be subject to an applicable exemption from registration requirements. The holders, at their sole discretion, may elect to effect a cashless exercise, and be issued exempt securities in accordance with Section 3(a)(9) of the 1933 Act. In the event the Company does not maintain an effective registration statement, the Company may be required to pay a daily cash penalty equal to 1% of the number of shares of Class 2 common stock due to be issued multiplied by any trading price of the Class 2 common stock between the exercise date and the share delivery date, as selected by the holder. Alternatively, the Company may deliver registered Class 2 common stock purchased by the Company in the open market. The Company may also be required to pay cash if it does not have sufficient authorized shares to deliver to the holders upon exercise.

Pre-funded warrants and warrants outstanding at December 31, 2020, and related activity for the year ended December 31, 2020 is as follows (reflects the number of shares of Class 2 common stock as if the warrants were converted to Class 2 common stock):

107

Description	Classification	Exercise price	Expiration date	Balance December 31, 2019	Issued	Exercised	Balance December 31, 2020
Pre-Funded Warrants	Liability	$ 0.0001	March 17,2025	—	11,750,000	(11,750,000 )	—
Warrants	Liability	$ 5.95	March 17,2025	—	19,000,000	—	19,000,000
			Total	—	30,750,000	(11,750,000 )	19,000,000

The Company estimated the fair value of the Warrant liability at December 31, 2020 at $6.35 per warrant using the Monte Carlo pricing model (Level 3) with the following weighted-average assumptions:

using the Monte Carlo pricing model (Level 3) with the following weighted-average assumptions:
Risk-free interest rate		0.40	%
Expected volatility		100	%
Expected term		4.7years
Expected dividendyield		0	%
Strikeprice	$	5.95
Fair value of common stock	$	8.26

Expected volatility is based on both historical and implied volatility of the Company's common stock since its initial public offering in 2018.

17. Stockholders’ Equity

Common and preferred stock

The Company’s certificate of incorporation authorized the Company to issue the following classes of shares with the following par value and voting rights as of December 31, 2020. The liquidation and dividend rights are identical among Class 1 common stock and Class 2 common stock, and all classes of common stock share equally in our earnings and losses.

equally in our earnings and losses.
	Par Value		Authorized	Voting Rights
Class 1 common stock	$ 0.0001		233,333,333	10 votes for each share
Class 2 common stock	$ 0.0001		500,000,000	1 vote for each share
Preferred stock	$ 0.0001		10,000,000	N/A

On September 30, 2020, 13,159,762 shares of Class 1 common stock, constituting all of the shares of Class 1 common stock that were issued and outstanding, were automatically converted into shares of Class 2 common stock, as the Class 1 common stock ceased to represent at least 10% of the outstanding common stock. Prior to the conversion, the Company had authorized 250,000,000 shares of Class 1 common stock. Upon conversion, 16,666,667 were retired, leaving 233,333,333 shares authorized, par value $0.0001 per share. There are no shares of Class 1 common stock outstanding as of December 31, 2020.

During the year ended December 31, 2020, the Company issued 16,131,487 shares of Class 2 common stock for gross proceeds of $127,041, under the at-the-market equity offering. Transaction costs of $2,541 were recorded net against the allocated gross proceeds in additional paid-in-capital. The warrants’ anti-dilution price protection features allow, for the period the warrants are outstanding, the Company to only issue up to $20,000 in aggregate gross proceeds under the Company’s at-the-market offering program at prices less than the exercise price of the warrants, and in no event more than $6,000 per quarter, at prices below the exercise price of the warrants, without triggering the warrant’s anti-dilution price protection features.

The Company’s future ability to pay cash dividends on Class 2 common stock is limited by the terms of the Senior Facility and cannot be paid without the consent of the lender.

On March 17, 2020, the Company closed the registered offering, issuing shares of the Company’s Class 2 common stock along with pre-funded warrants and warrants (refer to Note 16).

18. Stock-Based Compensation

Original Stock Option Plan

Certain employees and other service providers of the Company participate in the equity-based compensation plan of Privateer Holdings, Inc (the “Original Plan”) under the terms and valuation method detailed below. For the year ended December 31, 2020, the total stock-based compensation expenses associated with the

108

Original Plan was $702 (December 31, 2019 – $469 and 2018 – $359). There were no new grants under the Original Plan for the year ended December 31, 2020.

The fair value of each stock option to employees granted under the Original Plan was estimated on the date of grant using the Black-Scholes option pricing model with the following weighted-average assumptions:

	2020	2019 2018
Expected stock option life	—	— 5.15years
Expected volatility	—	— 48.82 %
Risk-free interest rate	—	— 2.35 %
Expected dividend yield	—	— - %

The expected life of the stock options represented the period of time stock options were expected to be outstanding and was estimated considering vesting terms and employees’ historical exercise and post-vesting employment termination behavior. Expected volatility was based on historical volatilities of public companies operating in a similar industry to Privateer Holdings. The risk-free rate is based on the United States Treasury yield curve in effect at the time of grant. The expected dividend yield was determined based on the stock option’s exercise price and expected annual dividend rate at the time of grant.

Stock option activity under the Original Plan

Stock option activity under the Original Plan
	Stock Options	Weighted- average exercise price	Weighted- average remaining contractual term(years)	Aggregate intrinsic value
Balance December 31,2019	3,014,004	$ 3.04	5.8	$ 44,108
Exercised	(1,076,156 )	1.80
Forfeited	(81,658 )	4.59
Cancelled	(66,440 )	3.81
Balance December 31,2020	1,789,750	$ 3.62	3.77	$ 25,077
Vested and expected to vest,December 31,2020	1,784,519	$ 3.61	3.76	$ 25,020
Vested and exercisable, December 31, 2020	1,731,626	$ 3.48	3.65	$ 24,449

The weighted-average fair values of all stock options granted in 2020 and 2019 were $0 and $0, respectively. The total intrinsic values of stock options exercised in 2020 and 2019 were $5,910 and $1,686, respectively. As of December 31, 2020, the total remaining unrecognized compensation expenses related to nonvested stock options amounted to $248 (2019 - $921), which will be amortized over the weighted-average remaining requisite service period of approximately 0.7 years (2019 – 0.8 years). The total fair values of stock options vested in 2020 and 2019 were $85 and $2,789, respectively.

New Stock Option and Restricted Stock Unit Plan

The Company adopted the 2018 Equity Incentive Plan (the “2018 EIP”) as amended and approved by stockholders in May 2018 under the terms and valuation methods detailed in our Annual Financial Statements. The 2018 EIP authorizes the award of stock options, restricted stock units (“RSUs”) and stock appreciation rights (“SARs”) to employees, including officers, non-employee directors and consultants and the employees and consultants of our affiliates. Shares subject to awards granted under the 2018 EIP that expire or terminate without being exercised in full, or that are paid out in cash rather than in shares, do not reduce the number of shares available for issuance under the 2018 EIP. Additionally, shares become available for future grant under the 2018 EIP if they were issued under the 2018 EIP and if the Company repurchases them or they are forfeited. This includes shares used to pay the exercise price of an award or to satisfy the tax withholding obligations related to an award. The maximum number of shares of common stock subject to stock awards granted under the 2018 EIP or otherwise during any one calendar year to any non-employee director, taken together with any cash fees paid by the Company to such non-employee director during such calendar year for service on the Board of Directors, will not exceed five hundred thousand dollars in total value, calculating the value of any such stock awards based on the grant date fair value of such stock awards for financial reporting purposes, or, with respect to the calendar year in which a nonemployee director is first appointed or elected to our Board of Directors, one million dollars.

109

Stock options represent the right to purchase shares of our Class 2 common stock on the date of exercise at a stated exercise price. The exercise price of a stock option generally must be at least equal to the fair market value of our shares of Class 2 common stock on the date of grant. The Company’s compensation committee may provide for stock options to be exercised only as they vest or to be immediately exercisable with any shares issued on exercise being subject to the Company’s right of repurchase that lapses as the shares vest. The maximum term of stock options granted under the 2018 EIP is ten years.

RSUs represent a right to receive Class 2 common stock or their cash equivalent for each RSU that vests, which vesting may be based on time or achievement of performance conditions. Unless otherwise determined by our compensation committee at the time of grant, vesting will cease on the date the participant no longer provides services to the Company and unvested shares will be forfeited. If an RSU has not been forfeited, then on the date specified in the RSUs, the Company will deliver to the holder a number of whole shares of Class 2 common stock, cash or a combination of shares of our Class 2 common stock and cash. Additionally, dividend equivalents may be credited in respect of shares covered by the RSUs. Any additional shares covered by the RSU credited by reason of such dividend equivalents will be subject to all of the same terms and conditions of the underlying RSU agreement to which they relate. The RSUs generally vest over a 3-or-4 year period. The fair value of RSUs are based on the share price as at date of grant.

SARs provide for a payment, or payments, in cash or shares of Class 2 common stock to the holder based upon the difference between the fair market value of shares of our Class 2 common stock on the date of exercise and the stated exercise price. The maximum term of SARs granted under the 2018 EIP is ten years. No SARs were issued to date.

The 2018 EIP permits the grant of performance-based stock and cash awards. The performance goals may be based on company-wide performance or performance of one or more business units, divisions, affiliates or business segments and may be either absolute or relative to the performance of one or more comparable companies or the performance of one or more relevant indices. The length of any performance period, the performance goals to be achieved during the performance period, and the measure of whether and to what degree such performance goals have been attained will be conclusively determined by the Board of Directors.

As of January 1, 2020, 17,037,421 shares of Class 2 common stock had been reserved for issuance under the 2018 EIP. The number of shares of Class 2 common stock reserved for issuance under the 2018 EIP will automatically increase on January 1 of each calendar year, for a period of not more than ten years, starting on January 1, 2019 and ending on and including January 1, 2027, in an amount equal to 4% of the total number of shares of our common stock outstanding on December 31 of the prior calendar year, or a lesser number of shares determined by our Board of Directors. The shares reserved include only the outstanding shares related to stock options and RSUs, and excludes stock options outstanding under the Original Plan.

For the year ended December 31, 2020, the total stock-based compensation expenses associated with the 2018 EIP was $29,014 (2019 – $31,373 and 2018 – $20,629).

The fair value of each stock option granted to employees under the 2018 EIP is estimated on the grant date using the Black-Scholes option pricing model with the following weighted average assumptions:

	Assumptions 2020	Assumptions 2020	Assumptions 2019 Assumptions 2018
Expected stock option life(years)		—	8.97years 5.79years
Expected volatility		—	61.33 % 58.54 %
Risk-free interest rate		—	2.10 % 2.92 %
Expected dividend yield		—	-% -%

The expected life of the award is estimated using the simplified method since the Company does not have adequate historical exercise data to estimate the expected term. Expected volatility is based on historical volatilities of public companies operating in a similar industry to the Company. A forfeiture rate is estimated at the time of grant to reflect the amount of awards that are granted but are expected to be forfeited by the award holder prior to vesting. The estimated forfeiture rate applied to these amounts is derived from management’s estimate of the future stock option forfeiture behavior over the expected life of the awards. The risk-free rate is based on the United States Treasury yield curve in effect at the time of grant.

Stock option and RSU activity for the Company under the 2018 EIP is as follows:

110

Time-based s tock option activity

Time-based_s_tock option activity
	Stock Options	Weighted- average exercise price	Weighted- average remaining contractual term(years)	Aggregate intrinsic value
Balance December 31,2019	5,307,130	$ 14.04	8.4	$ 44,297
Granted	—	—
Exercised	(703,393 )	7.76
Forfeited	(468,096 )	13.73
Cancelled	(226,082 )	13.20
Balance December 31,2020	3,909,559	$ 15.25	7.4	$ 1,700,194
Vested and expected to vest,December 31,2020	3,840,493	$ 15.10	7.4	$ 1,675,302
Vested and exercisable, December 31, 2020	3,142,175	$ 13.16	13.2	$ 1,423,560

The weighted-average fair values of time-based stock options granted in 2020 was $0 per share (2019 – $40.11 and 2018 – $7.74). The total intrinsic values of these stock options exercised in 2020, 2019 and 2018 were, $2,706, $29,655 and $0, respectively. As of December 31, 2020, the total remaining unrecognized compensation expenses related to non-vested stock options amounted to $9,696 (2019 – $23,649 and 2018 – $38,250), which will be amortized over the weighted-average remaining requisite service period of approximately 1.5 years (2019 – 1.9 years and 2018 - 2.8 years). The total fair value of stock options vested in 2020 were $34,001 (2019 - $16,708 and 2018 - $5,508).

Performance-based stock option activity

	Stock Options	Weighted- average exercise price	Weighted- average remaining contractual term(years)	Aggregate intrinsic value
Balance December 31,2019	520,000	$ 7.76	8.4	$ 4,872
Granted	—	—
Exercised	(520,000 )	7.76
Forfeited	—	—
Cancelled	—	—
Balance December 31,2020	—	$ —		$ —
Vested and expected to vest,December 31,2020	—	$ —		$ —
Vested and exercisable, December 31, 2020	—	$ —		$ —

The weighted-average fair values of all performance-based stock options granted in 2020 was $0 per share (2019 - $0 and 2018 - $4.15). The total intrinsic values of stock options exercised in 2020, 2019 and 2018 were $1,160, $5,054 and $0 respectively. As of December 31, 2020, the total remaining unrecognized compensation expenses related to non-vested stock options amounted to $0 (2019 – $0 and 2018 – $593), which will be amortized over the weighted-average remaining requisite service period of approximately 0 years (2019 – 0 years and 2018 - 0.6 years). The total fair value of stock options vested in 2020 were $0 (2019 - $1,246 and 2018 - $1,246).

111

Time-based RSU activity

Time-based RSU activity
	Time-based RSUs	Weighted-average grant-date fair value per share
Non-vested December 31,2019	1,423,392	$ 42.05
Granted	2,156,079	8.53
Vested	(619,021 )	35.24
Forfeited	(1,058,349 )	25.65
Cancelled	(17,711 )	19.93
Non-vested December 31, 2020	1,884,390	$ 15.22

As of December 31, 2020, there was approximately $22,046 (2019 - $41,898 and 2018 - $10,336) of total unrecognized compensation cost related to non-vested time-based RSUs that will be recognized as expenses over a weighted-average period of 1.6 years (2019 – 2.3 years and 2018 - 3.2 years). The total intrinsic values of timebased RSUs vested in 2020, 2019 and 2018 were $187, $3,446 and $0 respectively. The total fair value of timebased RSUs vested in 2020 were $21,815 (2019 - $4,667 and 2018 - $0)

Performance-based RSU activity

	Performance- based RSUs	Weighted-average grant-date fair value per share
Non-vested December 31,2019	265,625	$ 7.76
Granted	493,961	7.07
Vested	(218,750 )	7.76
Non-vested December 31, 2020	540,836	$ 7.13

As of December 31, 2020, there was approximately $1,950 (2019 - $330 and 2018 - $1,882) of total unrecognized compensation cost related to non-vested performance-based RSUs that will be recognized as expenses over a weighted-average period of 0.9 years (2019 – 1.0 year and 2018 - 1.7 years). The total intrinsic values of performance-based RSUs vested in 2020, 2019 and 2018 were $109, $46,423 and $0 respectively. The total fair value of performance-based RSUs vested in 2020 were $1,698 (2019 - $6,087 and 2018 - $ 0).

19. Accumulated Other Comprehensive Income (“AOCI”)

The components of AOCI, net of tax, were as follows:

The components of AOCI, net of tax, were as follows:
	Foreign Currency Translation Adjustments	Unrealized (loss) gain on available-for- sale debt securities	Total
Balance as at December 31,2018	$ 4,528	$ (765 )	$ 3,763
Cumulative effect adjustment from a transition to ASU 2016-01	—	803	803
Other comprehensive income(loss)	5,174	(21 )	5,153
Balance as at December 31,2019	9,702	17	9,719
Other comprehensive loss:
Change in foreign currencytranslation	(1,497 )	—	(1,497 )
Change in unrealizedgains on available-for-sale debt securities	—	(17 )	(17 )
Balance as at December 31, 2020	$ 8,205	$ —	$ 8,205

112

20. Commitments and Contingencies

Legal proceedings

In the normal course of business, the Company may become involved in legal disputes regarding various litigation matters. The Company records a loss contingency if the information available indicates that it is probable that a liability has been incurred at the date of the financial statements and the amount of loss can be reasonably estimated. As of December 31, 2020, in the opinion of management, no claims meet the criteria to record a loss contingency.

Purchase commitments

The following table reflects the Company’s future non-cancellable minimum purchase commitments for inventory as of December 31, 2020:

	Total	2021	2022	2023	2024	2025	Thereafter
Purchase commitments	$ 84,094	$ 84,094	$ —	$ —	$ —	$ —	$ —
Total	$ 84,094	$ 84,094	$ —	$ —	$ —	$ —	$ —

In 2018, the Company signed an agreement with Rose Lifescience Inc. (“Rose”) for distribution and marketing of product in Quebec in exchange for a minimum fee of $384 per annum for an initial term of five years, and agreed to purchase the lesser of 2,000 Kg per year or 40% of the production of Cannabis at a rate of 115% of cost of goods sold from the Rose facility. In September 2020, the Company signed an amendment to this agreement under which the Company is no longer obligated to purchase product from Rose nor pay the minimum fee. Instead, the amendment requires the Company to make approximately 40,000 kilograms equivalent Tilray product available in the province of Quebec through 2023 for Rose for sale and pay Rose a compensation fee based on net revenue sold in Quebec for an estimated compensation fee of approximately $8.0 million through 2023. As there is no firm commission fee commitment, it is excluded from the above schedule. Compensation fee expense is recorded as incurred.

In 2018, the Company entered into a Product and Trademark License Agreement with Docklight LLC, a related party (refer to Note 25), to use certain intellectual property rights in exchange for payment of royalty depending upon specified percentage of licensed product net sales. As the purchase commitment is an undeterminable variable amount, it is excluded from the above schedule.

Other commitments

The Company has payments on the convertible notes (refer to Note 14), ABG finance liability (refer to Note 4), the Senior Facility (refer to Note 15), and Portugal construction purchase commitments as follows:

	Total	2021	2022	2023	2024	2025	Thereafter
Convertible notes,	$ 319,535	$ 13,893	$ 13,893	$ 291,749	$ —	$ —	$ —
principal and interest
Senior Facility, principal	56,683	5,302	51,381	—	—	—	—
and interest
ABG finance liability	7,500	1,500	1,500	1,500	1,500	1,500	$ —
Portugal construction	2,778	2,778	—	—	—	—	—
commitments
Total	$ 386,496	$ 23,473	$ 66,774	$ 293,249	$ 1,500	$ 1,500	$ —

In the event the Company consummates the announced merger with Aphria Inc., the Company has agreed to pay its financial advisor a non-refundable $9,000 transaction fee on the date of closing.

21. Revenue from Contracts with Customers

The Company reports two segments: cannabis and hemp, in accordance with ASC 280 Segment Reporting. The Company generates revenues from the cannabis and hemp segments through contracts with customers, each with a single performance obligation, being the sale of products. The Company determines that revenue information

113

disclosed in business segment information in Note 28 disaggregates revenue into categories that depict how the nature, amount, timing and uncertainty of revenue and cash flows are affected by economic factors.

For certain long-term arrangements, the Company has performance obligations for goods it has not yet delivered. For these arrangements, the Company does not have a right to bill for the undelivered goods. The Company has determined that any unbilled consideration relates entirely to the value of undelivered goods. Accordingly, the Company has not recognized revenue, and has elected not to disclose amounts, related to these undelivered goods. As of December 31, 2020, other than accounts receivable, net of allowance for doubtful debts, the Company has no contract balances in the balance sheets.

22. General and Administrative Expenses

General and administrative expenses are comprised of the following items:

	Year ended December 31,	Year ended December 31,	Year ended December 31,
	2020	2019	2018
Salaries and benefits	$ 31,553	$ 39,565	$ 11,721
Stock-based compensation expenses	20,491	26,499	18,926
Other expenses	17,869	16,649	8,152
Professional fees	12,773	21,189	7,557
Loss on disposal ofpropertyand equipment	1,851	2,436	190
Travel expenses	937	4,565	2,031
Credit loss expenses	409	—	—
Total	$ 85,883	$ 110,903	$ 48,577

23. Income Taxes

For financial reporting purposes, loss before income taxes includes the following components:

	Year ended December 31,	Year ended December 31,	Year ended December 31,
	2020	2019	2018
United States	$ (168,480 )	$ (156,010 )	$ (42,418 )
Canada	(96,337 )	(151,736 )	(25,333 )
Portugal	(4,730 )	(11,781 )	(2,208 )
Other countries	(7,128 )	(10,092 )	(2,215 )
Total	$ (276,675 )	$ (329,619 )	$ (72,174 )

The (recoveries) expenses for income taxes consists of:

The (recoveries) expenses for income taxes consists of:
	Year ended December 31,
	2020	2019	2018
Current income tax(recoveries)expenses:
United States	$ (227 )	$ 151	$ —
Canada	(88 )	112	—
Other countries	89	134	34
Total	(226 )	397	34
Deferred income tax recoveries:
United States	$ (569 )	$ (4,390 )	$ (4,485 )
Canada	(4,909 )	(3,383 )	—
Other countries	102	(1,074 )	—
Total	(5,376 )	(8,847 )	(4,485 )
Income tax benefits, net	$ (5,602 )	$ (8,450 )	$ (4,451 )

114

The effective tax rate differs from the U.S. federal stautory rate as follows (in thousands):

The effective tax rate differs from the U.S. federal stautory	rate as follows (in thousands):	rate as follows (in thousands):	rate as follows (in thousands):
	Year ended December 31,
	2020	2019	2018
Loss before income taxes:	$ (276,675 )	$ (329,619 )	$ (72,174 )
Income tax benefits at statutoryrate	(58,076 )	(69,220 )	(15,157 )
Tax impact of foreign operations	(6,035 )	(9,193 )	(1,864 )
Foreign exchange and other	(2,349 )	1,015	1,399
Non-deductible expenses	1,576	483	5,331
Changes in enacted rates	—	(3 )	—
Change in fair value of warrant liability	21,060	—	—
Stock based and other compensation	3,376	2,113	—
Change in valuation allowance	34,846	66,355	5,840
Income tax benefits, net	$ (5,602 )	$ (8,450 )	$ (4,451 )

The tax effects of the temporary differences that give rise to the deferred tax assets and liabilities are as follows (in thousands):

follows (in thousands):
	Year ended December 31,
	2020	2019	2018
Deferred assets
Operatingloss carryforwards - United States	$ 28,575	$ 5,843	$ 4,173
Operatingloss carryforwards - Canada	69,100	59,755	13,723
Operatingloss carryforwards - Other Countries	5,806	5,158	607
Propertyand equipment	—	—	2,510
Currentlynondeductible interest	7,658	4,915	—
Partnershipinterests	34,869	21,546	—
Deferred financingcosts	214	208	27
Investment tax credits and relatedpool balance	566	180	57
Other	6,794	931	—
Total Deferred tax assets	153,582	98,536	21,097
Less valuation allowance	(149,655 )	(84,337 )	(14,433 )
Net deferred tax assets	3,927	14,199	6,664
Deferred tax liabilities
Propertyand equipment	(1,582 )	(5,800 )	(2,328 )
Intangible assets	(48,456 )	(54,814 )	(289 )
Equity portion of convertible notes	(3,163 )	(6,948 )	(8,471 )
Total deferred tax liabilities	(53,201 )	(67,562 )	(11,088 )
Net deferred tax liability	$ (49,274 )	$ (53,363 )	$ (4,424 )

On March 27, 2020, the Coronavirus Aid, Relief and Economic Security (“CARES”) Act was enacted and signed into law in the U.S. The CARES Act, among other things, permits U.S. net operating loss ("NOL") carryovers and carrybacks to offset 100% of U.S. taxable income for taxable years beginning before 2021. The CARES Act also contains modifications on the limitation of business interest for tax years beginning in 2019 and 2020. The modifications to Section 163(j) increase the allowable business interest deduction from 30% of adjusted taxable income to 50% of adjusted taxable income. The CARES Act results in increasing the allowable interest expense and NOL carryover deductions in 2020.

The Tax Cuts and Jobs Act (2017 Tax Act) was enacted on December 22, 2017 and reduced the U.S. statutory federal corporate tax rate from 35% to 21%. The Tax Act also contains additional provisions that are effective for the company in 2018, including a new tax on Global Intangible Low-Taxed Income (“GILTI”). Under U.S. GAAP, we are allowed to make an accounting policy choice to either (i) treat taxes due on future U.S. inclusions in taxable income related to GILTI as a current-period expense when incurred (the "period cost method"); or (ii) factor in such amounts into the measurement of our deferred taxes (the "deferred method"). The Company has made a policy decision to record GILTI tax as a current-period expense when incurred.

115

Effective January 1, 2018, the United States tax law provides a deduction for the foreign-source portion of dividends received from specified foreign corporations. As such, the Company does not maintain an indefinite reinvestment assertion on unremitted foreign earnings and has recorded a deferred tax liability, as necessary, for any estimated foreign, federal, or state tax liabilities associated with a future repatriation of foreign earnings.

At December 31, 2020, the Company had United States net operating loss carryforwards of approximately $135,817 that can be carried forward indefinitely and generally limited in annual use to 80% of the current year taxable income starting 2021. The Company has Canadian net operating loss carry-forwards of approximately $258,790 that can be carried forward 20 years and begin to expire in 2028. Management believes that it is morelikely-than-not that the benefit from certain United States and foreign net operating loss carryforwards will not be realized. In recognition of this risk, the Company has provided a valuation allowance on the deferred tax assets relating to these carryforwards. The net change in the total valuation allowance was an increase of $65,318 and $66,355 for the years ended December 31, 2020 and 2019, respectively.

The Company recognizes the financial statement impact of a tax position only after determining that the relevant tax authority would more-likely-than-not sustain the position following an audit. For tax positions meeting the more-likely-than-not threshold, the amount recognized in the financial statements is the largest impact that has a greater than fifty percent likelihood of being realized upon ultimate settlement with the relevant tax authority.

The total amount of gross unrecognized tax benefits (“GUTB”) was $0, $86, and $0 as of December 31, 2020, 2019 and 2018 respectively. The $86 decrease of GUTB in 2020 was attributable to unrecognized tax benefits as a result of tax positions taken during a prior period. The $86 increase of GUTB in 2019 was attributable to unrecognized tax benefits as a result of tax positions taken during a prior period. There is a reasonable possibility that the Company’s unrecognized tax benefits will change within twelve months due to audit settlements or the expiration of statute of limitations, but the Company does not expect the change to be material to the financial statements.

The Company recognizes interest and, if applicable, penalties for any uncertain tax positions. Interest and penalties are recorded as a component of income tax expenses. In the years ended December 31, 2020, 2019 and 2018, the Company recorded approximately $0, $0 and $0, respectively, of interest and penalty expenses related to uncertain tax positions. As of December 31,2020, and 2019, the Company had a cumulative balance of accrued interest and penalties on unrecognized tax positions of $0 and $0, respectively.

The Company and its subsidiaries are subject to United States federal income tax as well as the income tax of multiple state and foreign jurisdictions. The Company is not currently under audit in any jurisdiction for any period. Major jurisdictions where there are wholly owned subsidiaries of Tilray, Inc. which require income tax filings include the Canada, Portugal, Germany, and Australia. The earliest periods open for review by local taxing authorities are fiscal years 2016 for Canada, 2017 for Portugal, 2016 for Germany, 2017 for Australia, and 2018 for United States.

116

24. Supplemental Cash Flow Information[(1) ]

24. Supplemental Cash Flow Information(1)
	Year ended December 31,
	2020	2019 2018
Cashpaid for interest	$ 27,588	$ 28,206 $ 1,189
Cashpaid for income taxes	190	145 —
Non-cash financingactivities
Conversion ofpreferred stock to common stock	—	— 2
Exchange of convertible debt for common stock	(182,738 )	— —
Non-cash investing		— —
Alef acquisition	—	— 2,855
Acquisition of Manitoba Harvest	—	158,197 —
Acquisition of Natura	—	38,979 —
Acquisition of S&S	—	5,021 —
Investment in ABG Profit Participation Arrangement, net of receivable	—	97,544 —
Purchases of investments	$ —	$ 10,551 $ —

(1) For supplemental cash flow information related to leases, refer to Note 10.

25. Related-Party Transactions

In the normal course of business, the Company enters into related party transactions with certain entities under common control and joint ventures as detailed below.

Leafly Holdings, Inc. (“Leafly”)

The Company has an agreement with Leafly providing for data licensing activities. During the year ended December 31, 2020, operational expenses of $134 was recorded within general and administrative expenses in the statements of net loss and comprehensive loss (2019 - $272).

Docklight LLC (“Docklight”) royalty and management services

The Company pays Docklight a royalty fee pursuant to a brand licensing agreement which provides the Company with exclusive rights in Canada for the use of certain adult-use brands. During the year ended December 31, 2020, royalty fees of $1,178 were recorded within general and administrative expenses in the statements of net loss and comprehensive loss (2019 - $176). Refer to Note 20 for purchase commitments with Docklight.

Ten Eleven Management LLC (“Ten Eleven”)

In January 2020, the Company entered into a corporate services agreement with Ten Eleven Management LLC (“Ten Eleven”), pursuant to which Ten Eleven provides the Company with certain general administrative and corporate services for a service fee. This agreement was terminated in April 2020. In August 2020, the Company entered into a corporate services agreement with Ten Eleven pursuant to which Ten Eleven provides the Company with certain accounting services for a service fee. This agreement was terminated in October 2020. During the year ended December 31, 2020, management services of $71 was recorded within general and administrative expenses in the statements of net loss and comprehensive loss (2019 - $275).

The Company sub-leases a portion of certain office space to Ten Eleven. Ten Eleven’s lease payments are based on the pro-rata share of space that they occupy, with annual lease payments of $470. The sub-lease was terminated in May 2020. For the year ended December 31, 2020, $196 of sublease income is recorded in other income, net (2019 - $307).

Fluent and Cannfections

The Company has joint venture arrangements with a 50% ownership and voting interest in each of Fluent and Cannfections. Refer to Note 7 for details over transactions with these entities for the year ended December 31, 2020.

117

Aircraft Time Share Reimbursement

The Company had entered into an aircraft time-share agreement and a lease consent and subordination agreement with Brendan Kennedy, our Chief Executive Officer, whereby the Company had access to and use of an aircraft owned by Mr. Kennedy on an as-needed basis for business purposes. Pursuant to this arrangement, the Company reimbursed Mr. Kennedy for certain related aircraft expenses. During the year ended December 31, 2020, the Company incurred $261 of fees which is included in general and administrative expenses (2019 – $0).

Accounts payable due to related parties

At December 31, 2020, the Company has accounts payable due to related parties of $290 (December 31, 2019 - $68).

26. Financial Instruments

Credit risk

Credit risk is the risk of financial loss to the Company if a customer or counterparty to a financial instrument fails to meet its contractual obligations, and arises principally from the Company’s cash and cash equivalents, accounts receivable and short-term investments.

The Company’s cash and cash equivalents are deposited in major financial institutions in Canada, Australia, Portugal, Germany and the United States. To date, the Company has not experienced any losses on its cash deposits. Accounts receivable are unsecured and the Company does not require collateral from its customers.

The Company is also exposed to credit risk from the potential default by any of its counterparties on its financial assets.

The Company evaluates the collectability of its accounts receivable and provides an allowance for potential credit losses as necessary (refer to Note 8).

Due to the uncertainties associated with COVID-19, the Company may be unable to accurately predict the creditworthiness of its counterparties and their ability to meet their obligations. This may result in unforeseen additional credit losses.

Foreign currency risk

The Company conducts its business in several countries and in a variety of currencies, the most significant of which are the Canadian dollar and Euro. Consequently, the Company is exposed to foreign currency risk. A significant portion of the Company’s assets, liabilities, revenue, and expenses are denominated in Canadian dollars. A 10% change in the exchange rates for the Canadian dollar would affect the carrying value of net assets by approximately $45,944 as of December 31, 2020 (2019 - $12,457 and 2018 – $2,817), with a corresponding impact to accumulated other comprehensive income (loss). The Company is also exposed to risk related to changes in the value of the Euro due to its construction commitment in Portugal.

Interest rate risk

The Company’s exposure to changes in interest rates relates primarily to the Company’s outsanding debt. The Company is exposed to changes to the Canadian prime rate as the Senior Facility bears interest based on the Canadian prime rate plus 8.05%. The convertible notes bear interest at a fixed rate of 5% and are not publicly traded and, therefore, are not affected by changes in the market interest rates. A 1% change in the Canadian prime rate would have an impact of $425 to the statements of net loss and comprehensive loss for the year ended December 31, 2020.

Liquidity risk

The Company’s objective is to have sufficient liquidity to meet its liabilities when due. The Company monitors its cash balances and cash flows generated from operations to meet its requirements. As at December 31, 2020 and December 31, 2019, the most significant financial liabilities are accounts payable, accrued expenses and other current liabilities, and convertible notes and the Senior Facility.

118

Equity Price Risks

As of December 31, 2020, we held long-term equity investments at fair value and equity investments under the measurement alternative. These investment in equities were acquired as part of our strategic transactions. Accordingly, the changes in fair values of investment in equities measured at fair value or under the measurement alternative are recognized through other expense (income), net in the statements of net loss and comprehensive loss. Based on the fair value of investment in equities held as of December 31, 2020, a hypothetical decrease of 10% in the prices for these companies would reduce the fair values of the investments and result in unrealized loss recorded in other expense (income), net by $50. Similarly, based on the fair value of our warrant liability as of December 31, 2020, a hypothetical increase of 10% in the price for our common stock would increase the change in fair value of warrant liability by $5,800.

27. Fair Value Measurement

The Company complies with ASC 820, Fair Value Measurements, for its financial assets and liabilities that are re-measured and reported at fair value at each reporting period, and non-financial assets and liabilities that are re-measured and reported at fair value at least annually. In general, fair values determined by Level 1 inputs utilize quoted prices (unadjusted) in active markets for identical assets or liabilities. Fair values determined by Level 2 inputs utilize data points that are observable such as quoted prices, interest rates and yield curves. Fair values determined by Level 3 inputs are unobservable data points for the asset or liability, and includes situations where there is little, if any, market activity for the asset or liability.

The following tables present information about the Company’s assets and liabilities that are measured at fair value on a recurring basis as of December 31, 2020 and 2019 indicates the fair value hierarchy of the valuation techniques the Company utilized to determine such fair value:

	Quotedprices
	in active
	markets for	Other	Significant
	identical	observable	unobservable
	assets	inputs	inputs
	(Level 1)	(Level 2)	(Level 3)	Total
December 31,2020
Investments
Equityinvestments measured at fair value	$ 477	$ —	$ —	$ 477
Debt securities classified as available-for-sale	—	—	2,500	2,500
Warrant liability	—	—	(120,647 )	(120,647 )
Convertible Debt	—	(239,652 )	—	(239,652 )
Total recurring fair value measurements	$ 477	$ (239,652 )	$ (118,147 )	$ (357,322 )
	Quotedprices
	in active
	markets for	Other	Significant
	identical	observable	unobservable
	assets	inputs	inputs
	(Level 1)	(Level 2)	(Level 3)	Total
December 31,2019
Investments
Equityinvestments measured at fair value	$ 4,183	$ —	$ —	$ 4,183
Debt securities classified as available-for-sale	727	—	4,320	5,047
Acquisition-related contingent consideration	—	—	420	420
Total recurring fair value measurements	$ 4,910	$ —	$ 4,740	$ 9,650

Items measured at fair value on a recurring basis

The Company’s financial assets and liabilities required to be measured on a recurring basis are its equity investments measured at fair value, debt securities classified as available-for-sale, acquisition-related contingent consideration, and warrant liability.

119

Debt securities classified as available-for-sale and equity investments recorded at fair value: The estimated fair value is determined using quoted market prices, broker or dealer quotations or discounted cash flows.

Warrant liability: The warrants associated with the warrant liability are classified as Level 3 derivatives. Consequently, the estimated fair value of the warrant liability is determined using the Monte Carlo pricing model (refer to Note 16). Until the warrants are exercised, expire, or other facts and circumstances lead the warrant liability to be reclassified to stockholders’ equity, the warrant liability (which relates to warrants to purchase shares of Class 2 common stock) is marked-to-market each reporting period with the change in fair value recorded in change in fair value of warrant liability. Any significant adjustments to the unobservable inputs disclosed in the table below would have a direct impact on the fair value of the warrant liability.

Convertible Debt: This instrument is held at amortized cost. The estimated fair value is determined using quoted market prices near the reporting date and is classified as Level 2.

The opening balances of assets and liabilities categorized within Level 3 of the fair value hierarchy measured at fair value on a recurring basis are reconciled to the closing balances as follows:

	Debt securities classified as available-for- sale
		Warrant liability
Openingbalance as at January1,2020	$ 4,320	$ —
Additions	—	(69,414 )
Exercise	—	49,053
Settlements		—
Interest expenses,net	804	—
Change in fair value	(2,624 )	(100,286 )
Closing balance as at December 31, 2020	$ 2,500	$ (120,647 )

	Quantitative information about Level 3 fair value measurements	Quantitative information about Level 3 fair value measurements	Quantitative information about Level 3 fair value measurements
	Fair value at December 31, 2020		Unobservable input Range (weighted average)
		Valuation technique
			Discount rate 16.5%
Debt securities classified as available-for-sale			Probability of conversion/ prepayment nil
	$ 2,500	Discounted cash flow
			Probabilityof default nil
Warrant liability	$ (120,647 )	Monte Carlo	Volatility 100%
			Expected life 4.7 years

Items measured at fair value on a non-recurring basis

The Company's prepayments and other current assets, long lived assets, including property and equipment, goodwill and intangible assets are measured at fair value when there is an indicator of impairment and are recorded at fair value only when an impairment charge is recognized.

The estimated fair value of cash and cash equivalents, accounts receivable, net, accounts payable, accrued expenses and other current liabilities and Senior Facility at December 31, 2020 (December 31, 2019 – the fair value of all aforementioned, except the Senior Facility which was entered into in 2020) approximate their carrying value.

120

28. Business Segment Information

The Company has two operating segments based on major product categories: cannabis and hemp. These operating segments are also the Company’s reportable segments.

The cannabis segment cultivates, processes and distributes medical and adult-use cannabis products in a variety of formats, as well as related accessories, on a global basis. The hemp segment processes and distributes a diverse portfolio of hemp-based natural and organic food and wellness products on a global basis.

The results of each segment are regularly reviewed by the Company’s Chief Executive Officer, who is the Company’s chief operating decision maker, to assess the performance of the segment and make decisions regarding the allocation of resources. The Company’s chief operating decision maker uses revenue and gross profit as the measure of segment profit or loss. The accounting policies of each segment are the same as those set out under the summary of significant accounting policies in Note 2. There are no intersegment sales or transfers.

				Year ended December 31,	Year ended December 31,	Year ended December 31,
	2020				2019		2018
			Gross		Revenue	Gross profit (loss)	Revenue Gross profit
			profit
	Revenue		(loss)
Cannabis	$ 133,605		$ (3,575 )		$ 107,147	$ (42,302 )	$ 43,130 $ 14,275
Hemp	76,877		28,230		59,832	18,806	— —
Total	$ 210,482		$ 24,655		$ 166,979	$ (23,496 )	$ 43,130 $ 14,275

No asset information is provided for the segments because the Company’s chief operating decision maker does not receive asset information by segment on a regular basis.

Total revenue and gross profit for the reportable segments is equal to the Company’s consolidated revenue and gross profit.

and gross profit.
	Year ended December 31,
	2020	2019	2018
Grossprofit(loss)for the segments	$ 24,655	$ (23,496 )	$ 14,275
General and administrative expenses	(85,883 )	(110,903 )	(48,577 )
Sales and marketingexpenses	(54,666 )	(63,813 )	(15,828 )
Research and development expenses	(4,411 )	(9,172 )	(5,864 )
Depreciation and amortization expenses	(13,722 )	(11,607 )	(1,598 )
Impairment of assets	(61,114 )	(112,070 )	—
Acquisition-related income(expenses),net	—	31,427	(248 )
Loss from equitymethod investments	(5,983 )	(4,504 )	—
Foreign exchange(loss) gain,net	13,169	5,944	(7,234 )
Change in fair value of warrant liability	(100,286 )	—	—
Gain on debt conversion	61,118	—	—
Interest expenses,net	(39,219 )	(34,690 )	(9,110 )
Finance income from ABG	—	764	—
Other(expenses)income,net	(10,333 )	2,501	2,010
Loss before income taxes	$ (276,675 )	$ (329,619 )	$ (72,174 )

Sources of revenue were as follows:

Sources of revenue were as follows:
	Year Ended December 31,
	2020	2019	2018
Dried cannabis	$ 92,781	$ 82,753	$ 21,674
Cannabis extracts	39,986	24,139	21,179
Hemp products	76,877	59,832	—
Accessories and other	838	255	277
Total	$ 210,482	$ 166,979	$ 43,130

121

Channels of revenue were as follows:

	Year Ended December 31,	Year Ended December 31,	Year Ended December 31,
	2020	2019	2018
Cannabis
Adult-use	$ 83,828	$ 55,763	$ 3,521
Canada - medical	15,489	12,556	18,052
International - medical	33,886	13,378	2,912
Bulk	402	25,450	18,645
Total Cannabis revenue	$ 133,605	$ 107,147	$ 43,130
Hemp	76,877	59,832	—
Total	$ 210,482	$ 166,979	$ 43,130

Revenue attributed to geographic region based on the location of the customer was as follows:

	Year Ended December 31,	Year Ended December 31,	Year Ended December 31,
	2020	2019	2018
Canada	$ 120,581	$ 130,291	$ 40,209
United States	53,782	23,516	—
Other countries	36,119	13,172	2,921
Total	$ 210,482	$ 166,979	$ 43,130

Revenue includes excise duties of $19,143 for the year ended December 31, 2020 (2019: $13,136 and 2018: $1,200).

Long-lived assets consisting of property and equipment, net of accumulated depreciation, attributed to geographic regions based on their physical location were as follows:

geographic regions based on theirphysical location were as follows:
	December 31,
	2020	2019
Canada	$ 122,328	$ 144,065
Portugal	71,988	36,908
United States	5,182	3,171
Other countries	61	73
Total	$ 199,559	$ 184,217

Major Customers

Two customers, in the Cannabis segment, accounted for 19% and 11%, respectively, of revenue for the year ended December 31, 2020. One customer, in the Hemp segment, accounted for 15% of revenue for the year ended December 31, 2020. Two customers, one each in the Cannabis and Hemp segments, accounted for 13% each of revenue for the year ended December 31, 2019. One customer, in the Cannabis segment, accounted for 24% of the Company’s revenue for the year ended December 31, 2018.

Three customers accounted for 17%, 16% and 11%, respectively, of the Company’s accounts receivable balance as of December 31, 2020. Two customers accounted for 20% and 10%, respectively, of the Company’s accounts receivable balance as of December 31, 2019. Two customers accounted for 30% and 16%, respectively, of the Company’s accounts receivable balance as of December 31, 2018.

29. Business Combinations

Acquisition of Manitoba Harvest

On February 28, 2019, the Company completed the acquisition of all issued and outstanding shares of Manitoba Harvest. Manitoba Harvest develops and distributes a diverse portfolio of hemp-based natural food and wellness products and enables the Company to expand into the growing cannabidiol (“CBD”) product market in the United States.

122

Subsequent to the acquisition date, the Company revised the preliminary purchase price of the Manitoba Harvest acquisition to include working capital adjustments of $280 related to the acquisition. The Company also revised the preliminary allocation of the purchase price to assets acquired and liabilities assumed at the acquisition date, resulting in a $1,112 decrease in goodwill. The Company completed the final purchase price allocation for Manitoba Harvest. The goodwill of $126,881, assigned to the Hemp reportable segment (refer to Note 12), is attributable to factors such as market share, reputation with customers and vendors, and the skilled workforce of Manitoba Harvest. Goodwill is not deductible for tax purposes. The gross contractual amount of receivables as at the date of acquisition was $6,340, of which approximately $133 was not expected to be collected.

The financial results of Manitoba Harvest are included in the Company’s financial statements since acquisition close. The statements of net loss and comprehensive loss include revenue of $58,029 and net loss of $14,441 of Manitoba Harvest for the year ended December 31, 2019, respectively. The Company incurred acquisition costs of $1,328 for the acquisition of Manitoba Harvest.

Acquisition of Natura

On February 15, 2019, the Company acquired the remaining 97% issued and outstanding shares of Natura Naturals Holdings Inc. (“Natura”). Natura is licensed to cultivate and produce medical cannabis, expanding the Company’s capacity to supply high-quality branded cannabis products to the Canadian market. The Company revised the preliminary allocation of the purchase price to assets acquired and liabilities assumed at the acquisition date, resulting in a $2,340 increase in goodwill. The Company completed the final purchase price allocation. The goodwill of $29,314, assigned to the Cannabis reportable segment (refer to Note 12), is attributable to factors such as strong supply chain, quality of products and the skilled workforce of Natura. Goodwill is not deductible for tax purposes.

The financial results of Natura are included in the Company’s financial statements since acquisition close. The statements of net loss and comprehensive loss include revenue of $14,544 and net loss of $125 for the year ended December 31, 2019, respectively. The Company incurred acquisition costs of $824 for the acquisition of Natura.

Acquisition of S&S

On July 11, 2019, the Company acquired all issued and outstanding shares of Smith & Sinclair Ltd. (“S&S”), which crafts edible candies, fragrances and creative consumables in the United Kingdom and enables the Company to develop CBD-infused edibles and beverages as well as alcohol-infused edibles for distribution in Canada, United States and Europe. The financial results of S&S are included in the Company’s financial statements since acquisition close. The goodwill of $4,932 is assigned to the Hemp reportable segment (refer to Note 12). The statements of net loss and comprehensive loss include revenue of $1,633 and net loss of $2,774 for the year ended December 31, 2019, respectively.

123

The final allocations of the purchase price to assets acquired and liabilities assumed on the respective acquisition dates of Manitoba Harvest, Natura and S&S are as follows:

	Manitoba Harvest	Natura	S&S
Assets
Cash and cash equivalents	$ 5,534	169	137
Accounts receivable	6,207	109	264
Inventory	15,331	3,482	195
Prepayments and other current assets	1,030	166	125
Propertyand equipment	23,581	17,435	138
Intangible assets(1)(2)(3)	195,966	10,494	2,418
Goodwill	126,881	29,314	4,932
Total assets	374,530	61,169	8,209
Liabilities
Accountspayable	4,973	3,280	220
Accrued expenses and other current liabilities	4,911	876	89
Deferred tax liability	54,393	2,781	459
Total liabilities	64,277	6,937	768
Net assets acquired	$ 310,253	$ 54,232	$ 7,441

Intangible assets include:

(1) Manitoba Harvest: trademarks - $54,688, developed technology - $6,988 and customer relationships - $134,290

(2) Natura: licenses - $10,494

(3) S&S: trademarks - $1,670, patent - $690 and website - $58

The final purchase price of the Manitoba Harvest, Natura and S&S acquisitions are calculated as follows:

	Manitoba Harvest	Natura	S&S
Cashpaid on closing	$ 114,566	$ 15,253	$ 2,420
Cashpaid six months after closing	37,490	—	—
Class 2 common stock issued on closing(1)(2)(5)	96,844	15,099	3,189
Class 2 common stock issued six months after closing(1)	31,866	—	—
Workingcapital adjustment	280	—	—
Contingent consideration	29,207	20,007	1,812
Fair value ofpreviouslyheld interest (3)	—	1,565	—
Effective settlement ofpre-existingdebt (4)	—	2,308	—
Subscription rights	—	—	20
Total fair value of consideration transferred	$ 310,253	$ 54,232	$ 7,421

(1) For the acquisition of Manitoba Harvest, 1,209,946 shares of Class 2 common stock were issued on closing and 899,306 shares of Class 2 common stock were issued six months after closing.

(2) For the acquisition of Natura, 180,332 shares of Class 2 common stock were issued on closing.

(3) The fair value of the Company’s previously held interest in Natura on the acquisition date was determined based on the fair value of total consideration transferred and reflected book value on the acquisition date.

(4) The Company held C$3,000 convertible debt of Natura at the acquisition date. On acquisition, this debt and related accrued interest was effectively settled.

(5) For the acquisition of S&S, 79,289 shares of Class 2 common stock were issued on closing.

124

Supplemental pro forma information

The unaudited pro forma information for the periods set forth below gives effect to the acquisitions of Manitoba Harvest, Natura and S&S as if the acquisitions had occurred as of January 1, 2018. This pro forma information is presented for informational purposes only and is not necessarily indicative of the results of operations that actually would have been achieved had the acquisitions been consummated as of that time:

	Year ended December 31,	Year ended December 31,
	2019	2018
Revenue	$ 178,885	$ 107,786
Net loss	(325,760 )	(74,444 )
Net loss per share - basic and diluted	(3.24 )	(0.90 )

Acquisition-related (income) expenses, net

Acquisition-related (income) expenses, net for the years ended December 31 2019 and 2018 are comprised of the following items:

	Year ended December 31,	Year ended December 31,
	2019	2018
Acquisition and integration expenses	$ 15,487	$ 248
Change in fair value of contingent consideration	(46,914 )	—
Total	$ (31,427 )	$ 248

30. Subsequent Events

In January and February of 2021, holders of the Company’s warrants exercised 12,666,000 shares at the value of $5.95 per share, resulting in proceeds to the company of $75,363 as well as a reduction of the Company’s outstanding warrant liability for $80,000.

On February 9, 2021, the Company reached an agreement with the issuer of a convertible note to collect $2,500 as a prepayment and early termination. Payment in full was received on February 12, 2021.

31. Quarterly Financial Data (unaudited)

The following table contains selected quarterly data for 2020 and 2019. The information should be read in conjunction with the Company’s financial statements and related notes included elsewhere in this report. The Company believes that the following information reflects all normal recurring adjustments necessary for a fair presentation of the information for the periods presented. The operating results for any quarter are not necessarily indicative of results for any future period.

		Three months ended	Three months ended
	March 31,	June 30,	September 30, December 31,
2020
Revenue	$ 52,102	$ 50,414	$ 51,406 $ 56,560
Grossprofit	10,507	(5,824 )	3,330 16,642
Operatingloss	(71,250 )	(75,820 )	(32,772 ) (21,282 )
Net loss	(184,123 )	(81,687 )	(2,316 ) (2,947 )
Net lossper share—basic and diluted1	$ (1.73 )	$ (0.65 )	$ (0.02 ) $ (0.02 )
2019
Revenue	$ 23,038	$ 45,904	$ 51,101 $ 46,936
Grossprofit	5,385	12,273	15,853 (57,007 )
Operatingloss	(28,332 )	(32,961 )	(23,785 ) (216,624 )
Net loss	(29,369 )	(36,301 )	(36,351 ) (219,148 )
Net loss per share—basic and diluted1	$ (0.31 )	$ (0.37 )	$ (0.37 ) $ (2.14 )

¹ Earnings per share for the four quarters combined may not equal earnings per share for the year due to rounding.

125

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

To the Stockholders and the Board of Directors of Tilray Inc.

Opinion on the Financial Statements

We have audited the accompanying consolidated balance sheets of Tilray Inc. and subsidiaries (the "Company") as of December 31, 2020 and 2019, the related consolidated statements of net loss and comprehensive loss, and changes in stockholders’ equity (deficit), and cash flows for each of the three years in the period ended December 31, 2020, and the related notes (collectively referred to as the "financial statements"). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2020 and 2019, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2020, in conformity with accounting principles generally accepted in the United States of America.

We have also audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company's internal control over financial reporting as of December 31, 2020, based on criteria established in Internal Control - Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) and our report dated February 19, 2021, expressed an adverse opinion on the Company's internal control over financial reporting.

Basis for Opinion

These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company's financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.

Critical Audit Matters

The critical audit matters communicated below are matters arising from the current-period audit of the financial statements that were communicated or required to be communicated to the audit committee and that (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing separate opinions on the critical audit matters or on the accounts or disclosures to which they relate.

Inventory – Cannabis Costing — Refer to Notes 2 and 5 to the financial statements

Critical Audit Matter Description

Inventory is comprised of raw materials, finished goods and work-in-progress for cannabis and hemp products. Cost includes expenditures directly related to the manufacturing process as well as suitable portions of related production overheads, based on normal operating capacity. Inventory is stated at the lower of cost or net realizable value, determined using weighted average cost. For cannabis inventory, costs include pre-harvest, post-harvest, shipment and fulfillment, as well as related accessories.

The nature of the process for cannabis inventory costing is manual and requires management to use complex spreadsheet models updated monthly (“models”) to calculate a month by month ongoing cost of inventory. In addition, the models must use a variety of inputs and source data in order to calculate cost. Auditing the cost of inventory required an increased extent of audit effort.

How the Critical Audit Matter Was Addressed in the Audit

Our audit procedures related to the cost of cannabis inventory included the following, among others:

• Evaluated the complex spreadsheet models, and the inputs to such models, used to calculate the cost of cannabis inventory by:

• Evaluating the incorporation of the source data into the models, testing the formulas used and testing the computational accuracy.

126

• Testing purchases used in the models to third party source documentation.

• Testing production costs used in the models to actual costs incurred.

• Performing independent calculations of key inputs used in the models and comparing to inputs used by management.

• Testing management’s allocation of indirect costs between inventory products by assessing the appropriateness of the allocation method, recalculating the allocations and on a sample basis testing the underlying allocations by tracing to source documents.

• Testing production quantities used in the models by physically observing and verifying inventory quantities.

• As a result of the Company’s material weakness identified by the Company in the “Control Activity” component of Internal Control – Integrated Framework (2013) issued by COSO, we increased the extent of inventory physical observations and verifications, increased the extent of testing where sampling methodology was used, and utilized third party source documents in the performance of our testing procedures.

Goodwill and Indefinite-lived Intangible Assets— Refer to Notes 2, 11 and 12 to the financial statements

Critical Audit Matter Description

The Company performs an annual assessment of the impairment for goodwill and indefinite-lived intangible assets, or a more frequent assessment when events or circumstances indicate that the fair value of a reporting unit is less than its carrying value and an impairment may have occurred. As at December 31, 2020, the Company performed their annual assessment including a quantitative assessment. This assessment required management to make significant estimates and judgements relating to forecasted revenues, gross margins and operating margins, and discount rate. Changes in these assumptions could have a significant impact on either the fair value of the hemp reporting unit, the amount of any goodwill and indefinite-lived intangible assets impairment charge, or both. The fair value of the hemp reporting unit was determined to exceed its carrying value and no impairment charge was recorded.

Performing audit procedures to evaluate if the fair value of the hemp reporting unit exceeded its carrying value required a high degree of auditor judgment and an increased extent of audit effort, including involving fair value specialists.

How the Critical Audit Matter Was Addressed in the Audit

Our audit procedures related to the evaluation of the fair value of the hemp reporting unit against its carrying value included the following, among others:

• Evaluated management’s ability to accurately forecast revenues, gross margins and operating margins by comparing actual results to management’s historical forecasts.

• With the assistance of fair value specialists, developed an independent discounted cash flow model to estimate the fair value of the hemp reporting unit by:

• Determining forecasted revenues, gross margins and operating margins by considering:

  • Historical revenues, gross margins and operating margins;

  • Internal communications with management;

  • Underlying analyses detailing business strategies and growth plans;

  • Analyst and industry reports for the Company and peer companies operating in food and / or CBD.

• Determining an appropriate discount rate based on source information, industry data and benchmarks.

• Compared the independent estimate of the fair value of the hemp reporting until against its carrying value.

/s/ Deloitte LLP

Chartered Professional Accountants Vancouver, Canada February 19, 2021 We have served as the Company's auditor since 2017.

127